DAFTAR PUSTAKA

AGGARWAL PK, J. V., SAKHUJA V, KARUMANCHI SA, JHA V. 2006. Low Urinary Placental Growth Factor is A Marker of Pre-eclampsia. *Kidney International* 69**,** Pp**.** 621–4.

ABRAMS G. 2012. Patofisiologi Vol.1 : Konsep Klinis Proses-Proses Penyakit, Gangguan Sirkulasi : Aterosklerosis. *EGC*, 7, Pp. 104 - 107.

BARISONI L. AND MUNDEL P. 2003. Podocyte Biology and The Emerging Understanding of Podocyte Diseases. *Am J Nephrol*, 23, Pp.353-360.

BOLDT M.A. AND CARLETON P.F. 2012. Patofisiologi Vol.1 : Konsep Klinis Proses- Proses Penyakit, Penyakit Aterosklerotik Koroner : Hipertensi. *EGC*, 31, Pp. 529-534.

BELCHER J.M. AND PARIKH C.R. 2019. Acute Kidney Injury Diagnostics and Biomarkers. *Acute Kidney Injury*, 5 (47), Pp.713-724.

BUHIMSCHI CS, N. E., FUNAI E, RICHMAN S, GULLER S, LOCKWOOD CJ, ET AL 2005. Urinary Angiogenic Factors Cluster Hypertensive Disorders And Identify Women With Severe Preeclampsia. *American Journal of Obstetrics and Gynecology,* 192**,** 734–41.

BUHIMSCHI CS, B. M., DULAY AT, LEE S, WEHRUM M, ZHAO G, ET AL 2010. The Role of Urinary Soluble Endoglin in The Diagnosis of

Pre-eclampsia: Comparison with Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio. *BJOG,* 117**,** 321-30.

COLLINO F, B. B., GERBAUDO E, MAROZIO L, PELISSETTO S, BENEDETTO C, ET AL. 2008. Preeclamptic Sera Induce Nephrin Shedding From Podocytes Through Endothelial-1 Release by Endothelial Glomerular Cells. *American Journal of Physiology Renal Physiology* 294**,** F1185–94.

CORMICK, G. *ET AL.* 2016. Inter-Pregnancy Interval And Risk Of Recurrent Pre-Eclampsia : Systematic Review And Meta-Analysis', *Reproductive Health*. Reproductive Health, 13(83), Pp. 1–10. Doi: 10.1186/S12978-016-0197-X.

CORNELIS T., ODUTAYO A., KEUNEN J., AND HLADUNEWICH M. 2011. The Kidney in Normal Pregnancy and Preeclampsia. *Seminars in Nephrology*, 31(1), Pp.4-14. Doi : 10.1016/j.semnephol.2010.10.002.

CRAICI L.M., E. A. 2014. Podocyturia Predates proteinuria and Clinical features of Preeclampsia : A longitudinal Prospective Study. *Hypertension,* 61(6)**,** 1289-1296.

CUNNINGHAM F.G, E. A. 2010. Obstetri Williams edisi 23. *Hipertensi Dalam Kehamilan,* 2**,** 740-786.

D'AMICO G. AND BAZZI CLAUDIO. 2003. Pathophysiology of Proteinuria. *Kidney International,* 63, Pp. 809-825.

DENHEZ B. AND GERALDES P. 2017. Regulation of Nephrin Phosphorylation in Diabetes and Chronic Kidney Injury. Springer Nature Singapore Pte Ltd. Doi : 10.1007/5584_2017_62.

DESPOPOULUS A., S. S. 2003. Color Atlas of Physiology 5th *Kidney, Salt, and Water Balance*.

DUCKITT, K. AND HARRINGTON, D. 2005. Risk Factors For Pre-Eclampsia At Antenatal Booking: Systematic Review Of Controlled Studies, *Bmj*, 0(March), Pp. 1–7. Doi: 10.1136/Bmj.38380.674340.E0.

FURUTA I. 2017. Association between Nephrinuria, Podocyturia,and Proteinuria in Women with Pre-Eclampsia.

HA, T. 2013. Roles of Adaptor Proteins in Podocyte biology. *World Journal of Nephrology*.

GAILLARD, R. *E. A..* 2009. Maternal Age During Pregnancy Is Associated With Third Trimester Blood Pressure Level : The Generation R Study, *American Journal Of Hypertension*. Nature Publishing Group, 24(9), Pp. 1046–1053. Doi: 10.1038/Ajh.2011.95.

GAROVIC V. D. 2007. Glomerular Expression of Nephrin and Synaptopodin, but not Podocin, Is Decreased in Kidney Sections from Women with Preeclampsia. *Journal of Nephrology Dialysis Transplantation*.

GAROVIC V.D., E. A. 2007. Urinary Podocyte Excretion as A Marker For Preeclampsia. *Am J Obstet Gynecol***,** 196(4): 287-8.

GAROVIC V.D., E. A. 2014. The Role of the Podocyte in Preeclampsia. *Clinical Journal of the American Society of Nephrology : CJASN,* 9(8)**,** 1377-1385.

GATHIRAM P., MOODLEY J. 2016. Pre-eclampsia : Its Pathogenesis and Pathophysiology. *Cardiovascular Journal*, 27(2), Pp.71-78.

GILANI S. I., E. A. 2017. Urinary Extracellular Vesicles of Podocyte Origi and Renal Injury in Preeclampsia. *Journal of the American Society of Nephrology : JASN,* 28(11)**,** 3363-3372.

GRUM, T., HINTSA, S. AND HAGOS, G. 2018). Dietary Factors Associated With Preeclampsia Or Eclampsia Among Women In Delivery Care Services In Addis Ababa , Ethiopia : A Case Control Study', *Bmc Research Notes*. Biomed Central, Pp. 1–5. Doi: 10.1186/S13104-018-3793-8.

GUNAWAN W., J. C. E., BANGSAWAN N., 2017. Faktor Risiko Kematian Maternal di Rumah Sakit Umum Pusat Wahidin Sudirohusodo dan Jejaringnya Periode 01 Januari - 31 Desember 2016. *HOGSI*.

JALANKO H. 2003. Pathogenesis of Proteinuria : Lessons Learned From Nephrin and Podocin. *Pediatr Nephrol*, 18 : Pp.487-491, Doi : 10.1007/s00467-003-1173-6.

JEYABALAN A, AND CONRAD KP. 2007. Renal Function During Normal Pregnancy And Preeclampsia. *Frontiers in Bioscience*, (12),Pp. 2425-2437. **DOI:10.2741/2244.**

JIM B. 2014. A Comparison of Podocyturia, Albuminuria, and Nephrinuria in Predicting the Development of Preeclampsia: A Prospective Study.

JONES N, NEW LA, FORTINO MA, EREMINA V, RUSTON J, BLASUTIG IM, AOUDJIT L, ZOU Y, LIU X, YU G-LL, TAKANO T, QUAGGIN SE, PAWSON T. 2009. Nck Proteins Maintain The Adult Glomerular Filtration Barrier. *J Am Soc Nephrol*, 20(7), Pp. 1533–1543.

JUNG Y. J., *ET AL*. 2017. The Level of Serum and Urinary Nephrin in Normal Pregnancy and Pregnancy with Subsequent Preeclampsia.*Yonsei Medical Journal,* 58(2), Pp.401-406. Doi : 10.3349/ymj.2017.58.2.401.

KANDASAMY Y., E. A. 2014. Biomarker Research. *Nephrin- a Biomarker of Early Glomerular Injury*.

KARUMANCHI S A, L. K.-H., AUGUST PHYLLIS 2017. Preeclampsia : Pathogenesis. *uptodate*.

KHASHAN A. S., EVANS M., *ET AL*. 2019. Preeclampsia And Risk Of End Stage Kidney Disease : A Swedish Nationwide Cohort Study. *Plos Med*, 16(7): e1002875. Doi : 10.1371/journal.pmed.1002875.

KOSTOVSKA I., TRAJKOVSKA K. T., CEKOVSKA S., SPASOVSKI G., AND LABUDOVIC D. 2016. Nephrin and Podocalyxin-New Podocyte Proteins for Early Detection of secondary Nephropathies. BANTAO Journal, 14(1), Pp.11-16. Doi : 10.1515/bj-2016-0003.

KUMARI, N., DASH, K. AND SINGH, R. (2016) ‘Relationship between Maternal Age and Preeclampsia .’, *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*, 15(12), pp. 55–57. doi: 10.9790/0853-1512085557.

LEVENO, K. J. *ET AL.* (2018) *Willliams Obstetrics 25th edition*. 25th edn. Edited by J. S. Dashe. New York: McGraw-Hill Education.

LI X, CHUANG PY, D’AGATI VD, DAI Y, YACOUB R, FU J, XU J, TAKU O, PREMSRIRUT PK, HOLZMAN LB, HE JC. 2015. Nephrin Preserves Podocyte Viability And Glomerular Structure And Function In Adult Kidneys. *J Am Soc Nephrol*, 26(10), Pp. 2361–2377.

LUO, Z. *E. A..* 2007. The Effects And Mechanisms Of Primiparity On The Risk Of Pre-Eclampsia : A Systematic Review’, *Paediatric And Perinatal Epidemiology*, 21, Pp. 36–45.

MORKEN N.H., TRAVLOS G. S., WILSON R.E., EGGESBO M., LONGNECKER M.P., 2014. Maternal Glomerular Filtration Rate in Pregnancy and Fetal Size. *Plos One,* 9(7) : e101897. Doi:10.1371/journal.pone.0101897.

MREMA, D. *ET AL.* 2018. ‘The association between pre pregnancy body mass index and risk of preeclampsia : a registry based study from Tanzania’, *BMC Pregnancy and Childbirth*. BMC Pregnancy and

Childbirth, Pp. 1–8.

MUNDEL P. AND SHANKLAND S.J. 2002. Podocyte Biology and Response to Injury. J Am Soc Nephrol 13 , Pp. 3005-3015. Doi : 10.1097/01.ASN.0000039661.06947.FD

NAKATSUE T, K. H., HAN GD, ET AL. 2005. Nephrin and Podocin Dissociate at the Onset of Proteinuria in experimental Membranous Nephropathy. *Kidney International,* 67(6)**,** 2239-2253.

NEW LA, MARTIN CE, SCOTT RP, PLATT MJ, CHAHI KA, STRINGER CD, LU P, SAMBORSKA B, EREMINA V, TAKANO T, SIMPSON JA, QUAGGIN SE, JONES N. 2016. Nephrin Tyrosine Phosphorylation Is Required To Stabilize And Restore Podocyte Foot Process Architecture. *J Am Soc Nephrol*, 27:2422-2435. Doi : 10.1681//ASN.2015091048.

NG DPK., E. A. 2011. Nephrinuria Associates With Multiple Renal Traits in Type 2 Diabetes. *Nephrol Dial Transplant,* 26**,** 2508–2514.

NURDADI SALEH NW, D. 2016. Pedoman Nasional Pelayanan Kedokteran, Diagnosis dan Tatalaksana Pre Eklampsia. Perkumpulan Obstetri dan Ginekologi Indonesia Himpunan Kedokteran Feto Maternal.

OLIVERIO A. L., ZEE J. , ET AL. 2019. Renal Complications in Pregnancy Preceding Glomerulonephropathy Diagnosis. *Kidney International Reports*, 4, Pp. 159-162.

OPITASARI, C. AND ANDAYASARI, L. 2014. Parity , Education Level And Risk For (Pre-) Eclampsia In Selected Hospitals In Jakarta, *Health Science Indonesia*, 5(1), Pp. 35–39.

PAGANI, F. AND CANTALUPPI, V. 2019. Renal Injury During Preeclampsia : Role of Extracellular Vesicles. *Nephron Clinical Practice*, 143, Pp.197-201.

PEREMPUAN, Y. K. 2017. Akses Universal Pelayanan Kesehatan Seksual dan Reproduksi Profil Indonesia. 7.

PRICE S.A. AND WILSON L.M. 2012. Patofisiologi Vol.2 : Konsep Klinis Proses-Proses Penyakit, Gangguan Sistem Ginjal *EGC*, 6(8), Pp. 865-1004.

PATRAKKA J, TRYGGVASON K. 2007. Nephrin-A Unique Structural And Signaling Protein Of The Kidney Filter. *Trends Mol Med,* 13(9), Pp. 396–403.

RAMBALDI, M. AND PAIDAS, M. 2013. 'Hypertensive Disorders', in Cohen, W. R. and August, P. (eds) *Obstetric Medicine : Management of Medical Disorders in Pregnancy*. People's Medical Publishing House, pp. 158–161.

RANA, S. *ET AL.* 2019. 'Compendium on the Pathophysiology and Treatment of Hypertension', pp. 1094–1112. doi: 10.1161/CIRCRESAHA.118.313276.

RESLAN, O. M. AND KHALIL, R. A. 2010. Molecular And Vascular Targets In The Pathogenesis And Management Of The Hypertension Associated With Preeclampsia', *Cardiovascular & Hematological Agents In Medicinal Chemistry*, 8, Pp. 204–226.

RUOTSALAINEN V., L. P., TRYGGVASON K. 1999. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. *Cell Biology***,** 7962-7967.

SAADAT, M. *ET AL.*. 2007. Maternal And Neonatal Outcomes In Women With Preeclampsia, *Taiwan J Obstet Gynecol*, 46(3), Pp. 255–259.

SEELY, E. W. AND ECKER, J. 2014. Chronic Hypertension In Pregnancy, *Circulation*, 129(11), Pp. 1254–1261. Doi: 10.1161/Circulationaha.113.003904.

SEKULIC M., S. S. P. 2013. A Compendium of Urinary Biomarkers indicative of Glomerular Podocytopathy. *Pathology Research International*.

SHAMSI U, E. A. 2013. Epidemiology and risk factors of preeclampsia; an overview of observational studies. *Us National Library of Medicine enlisted journal,* 4**,** 292-300.

SHAO, Y. *ET AL.* 2017. 'Pre-pregnancy BMI , gestational weight gain and risk of preeclampsia : a birth cohort study in Lanzhou , China', *BMC Pregnancy and Childbirth*. BMC Pregnancy and Childbirth, 17, pp. 1–8. doi: 10.1186/s12884-017-1567-2.

SHERWOOD L. 2010. The Urinary System. *Human Physiology from Cells to Systems,* 7**,** 511-556.

SKJÆRVEN, R., WILCOX, A. J. AND LIE, R. T. 2002. The Interval Between Pregnancies And The Risk Of Preeclampsia, *New England Journal Of Medicine*, 346(1), Pp. 33–38.

SON GH, E. A. 2013. Comparison of Serum and Urinary Nephrin Levels Between Normal Pregnancies and Severe Preeclampsia. *European Journal of Obstetrics & Gynecology and Reproductive Biology*.

SON G.H., Et Al., 2011. Urinary Excretion of Nephrin in Paatients with Severe Preeclampsia, Hypertension in Pregnancy. *Informa Healthcare USA, John Hopkins University*, 30, Pp.408-413.

STILLMAN I., AND KARUMANCHI S. A. 2007. The Glomerular Injury of Preeclampsia. *Journal of American Society of Nephrology*, 18 (8), Pp.2281-4. DOI: 10.1681/ASN.2007020255.

STREVENS H., SWENSSON D.W., HANSEN A., HORN T., ET AL. 2003. Glomerular Endotheliosis in Normal Pregnancy and Pre-eclapmsia. *BJOG*, 110(9), Pp.831-6.

SUBKI, A. H. AND ALGETHAMI, M. R. 2018. Prevalence, Risk Factors, And Fetal And Maternal Outcomes Of Hypertensive Disorders Of Pregnancy: A Retrospective Study In Western Saudi Arabia, *Oman Medical Journal*, 33(5), Pp. 409–415. Doi: 10.5001/Omj.2018.75.

SUSALIT E., ET AL. 2004. Buku Ajar Ilmu Penyakit Dalam Jilid II, Edisi

Ketiga : Ginjal - Hipertensi. *Balai Penerbit FKUI*, 4(21-23), Pp.453 - 489.

TRYGGVASON K, P. J. 2010. Molecular Make-Up of The Glomerular Filtration Barrier. *Biochemical and Biophysical Research Communications,* 396**,** 164-169.

VANEK, M. *E. A..* 2004. Chronic Hypertension And The Risk For Adverse Pregnancy Outcome After Superimposed Pre-Eclampsia', *International Journal Of Gynecology And Obstetrics*, 86, Pp. 7–11. Doi: 10.1016/J.Ijgo.2004.03.006.

VIKSE BE, *E. A*. 2008. Pre-eclampsia and the risk of end-stage renal disease. *N Engl J Med;* 359: 800-809.

WANG Y. 2012. Increased Urinary Excretion of Nephrin, Podocalyxin, And Big-H3 In Women With Preeclampsia. *American Journal of Renal Physiology.*

WO´JTOWICZ A. , E. A. 2019. Early- And Late-Onset Preeclampsia: A Comprehensive Cohort Study Of Laboratory And Clinical Findings According To The New ISHHP Criteria. *Hindawi International Journal of Hypertension*. Doi : 10.1155/2019/4108271.

XUEZHU LI. AND CIJIANG J.HE. 2015. An Update : The Role of Nephrin Inside and Outside the Kidney. *Springer*, 58 (7), Pp. 649-657.

YAMADA T, E. A. 2016. Isolated Gestational Proteinuria Preceding The Diagnosis of Preeclampsia *Isolated Gestational Proteinuria Preceding The Diagnosis of Preeclampsia,* 95.

ZHAI T, E. A. 2016. Feasibility of Nephrinuria as a screening tool for the risk of pre-eclampsia: prospective observational study.

ZHANG A. AND HUANG S. 2012. Progress in Pathogenesis of Proteinuria. *International Journal of Nephrology.* Doi : 10.1155/2012/314251.

Lampiran 1

NASKAH PENJELASAN UNTUK RESPONDEN

Selamat Pagi/ Siang/ Sore, ibu. Saya dr. Wenny Yaury, yang akan melakukan penelitian tentang "Hubungan Antara Nephrinuria Dan Preeklampsia Berat “. Penelitian ini untuk membuktikan bahwa terdapat hubungan antara nephrinuria dan preeklampsia berat. Dimana hal ini bila terbukti, dapat mendukung untuk penelitian lebih lanjut dalam bidang kebidanan dan kandungan dalam hal pengembangan keilmuannya, serta berpotensial untuk ditemukannya biomarker baru dalam mendeteksi preeklampsia. Penelitian ini membutuhkan total 88 subyek penelitian.

Karena itu kami sangat mengharapkan ibu bersedia untuk ikut dalam penelitian ini secara sukarela dan mengizinkan kami menggunakan data ibu dalam laporan tertulis maupun laporan secara lisan. Bila ibu bersedia kami mengaharapkan ibu memberikan persetujuan secara tertulis. keikutsertaan ibu dalam penelitian ini bersifat sukarela tanpa paksaan. Oleh karena itu ibu berhak untuk menolak atau mengundurkan diri tanpa risiko kehilangan hak untuk mendapatkan pelayanan kesehatan di rumah sakit ini.

kalau ibu setuju untuk berpartisipasi, kami akan menanyakan beberapa hal antara lain data pribadi ibu, riwayat kesehatan ibu, riwayat kehamilan. kami juga akan melakukan pemeriksaan fisik berupa pengukuran tekanan darah, berat badan, tinggi badan, indeks massa tubuh, dan juga pencatatan hasil pemeriksaan laboratorium ibu selama dirawat di rumah sakit berupa sampel darah dan urin. Dalam penelitian ini, sampel yang akan saya ambil hanya berupa urin dari ibu untuk saya teliti lebih lanjut. Sebagai subyek penelitian, ibu tidak dipungut biaya apapun terkait pemeriksaan sampel urin ibu yang akan diteliti.

Penelitian ini tidak memiliki efek samping atau tidak akan menimbulkan kerugian pada ibu.

Kami menjamin keamanan dan kerahasiaan semua data pada penelitian ini. Data akan disimpan dengan baik dan aman, sehingga hanya dapat dilihat oleh yang berkepentingan saja. Demikian juga dengan penyajian secara tertulis, maupun laporan lisan akan dirahasiakan. Data penelitian ini akan disajikan pada :

- Forum ilmiah Program Pendidikan Dokter Spesialis Obstetri dan Ginekologi Fakultas Kedokteran Universitas Hasanuddin.
- Publikasi pada majalah ilmiah dalam dan luar negeri.

Bila masih ada hal yang belum jelas atau belum dimengerti dengan baik, ibu diberikan kesempatan untuk menanyakan semua hal yang belum jelas sehubungan dengan penelitian ini pada saya : dr. Wenny Yaury (082194964853).

Jika ibu setuju untuk berpartisipasi, diharapkan menandatangani surat persetujuan mengikuti penelitian. Atas kesediaan dan kerjasamanya, kami ucapkan banyak terima kasih.

Identitas Peneliti

Nama : dr. Wenny Yaury

Alamat : PPDS Obgin FK UNHAS

Telepon : 082194964853

DISETUJUI OLEH KOMISI PENELITIAN KESEHATAN FAK. KEDOKTERAN UNHAS

Tgl. ……

Lampiran 2

FORMULIR PERSETUJUAN MENGIKUTI PENELITIAN SETELAH MENDAPAT PENJELASAN

Yang bertanda tangan dibawah ini :

Nama :

……..

Umur :

……...

Alamat :

……...

Dengan ini menyatakan bahwa setelah saya mendapatkan penjelasan serta memahami sepenuhnya maksud dan tujuan penelitian ini.

Saya menyatakan setuju untuk ikut serta dalam penelitian ini. Untuk itu saya bersedia dan tidak keberatan mematuhi semua ketentuan yang berlaku dalam penelitian ini dan memberikan keterangan yang sebenarnya. Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bias menolak ikut atau mengundurkan diri dari penelitian ini tanpa kehilangan hak saya untuk mendapat pelayanan kesehatan. Juga saya berhak bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya juga mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini, akan ditanggung oleh peneliti. Demikian juga biaya perawatan dan pengobatan bila terjadi hal-hal yang tidak diinginkan akibat penelitian ini, akan dibiayai oleh peneliti.

Demikianlah pernyataan ini saya buat dengan penuh kesadaran untuk dapat dipergunakan sebagaimana mestinya.

	NAMA	TANDA TANGAN	Tanggal
1.	……	…….	……..
2.	……	…….	……..

Penanggung Jawab Penelitian

Nama : dr. Wenny Yaury
Alamat : PPDS Obgin FK UNHAS
Telepon : 082194964853

Penanggung Jawab Medis

Nama : Dr.dr. Isharyah Sunarno,Sp.OG (K)
Alamat : PPDS Obgin FK UNHAS
Telepon : 0811461814

Lampiran 3

FORMULIR PENELITIAN

HUBUNGAN ANTARA NEFRINURIA DAN PREEKLAMPSIA BERAT

I. IDENTITAS PASIEN

1. Nama : …….....
2. Rumah Sakit / No. Reg : ……
3. Tanggal MRS : ……
4. Pekerjaan : ……
5. Pendidikan : ……
6. Pekerjaan Suami : ……
7. Alamat : ……
8. Suku bangsa : ……
9. No.HP / Telepon : ……

II. DATA UMUM PASIEN

1. Tanggal Lahir/ Umur : …….....
2. Umur pertama menikah : …….....
3. Berapa kali menikah : …….....
4. Lama perkawinan : …….....
5. G P A : …….....

6. HPHT : …….....
7. Berat Badan : …….....
8. Tinggi Badan : …….....
9. IMT (BB/TB^2) : sebelum hamil……...setelah hamil….....
10. Kenaikan BB : …….....
11. Tekanan Darah : …….....

III. DATA KLINIS PASIEN

1. Keadaan Umum : …….....
2. Keluhan : …….....
3. Riwayat Penyakit : …….....
4. Riwayat Operasi : ……..
5. Riwayat Kontrasepsi : …….....
6. Riwayat Penyakit keluarga : ……

IV. PEMERIKSAAN LABORATORIUM PASIEN

1. Darah Rutin
    a. Wbc : ……
    b. Hb : ……
    c. Plt : ……

d. MCV :……

e. MCH :……

f. MCHC :……

g. GDS : ……

2. Urin

a. Protein : ……

b. Nefrin : ……...

Lampiran 4

KEMENTERIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
KOMITE ETIK PENELITIAN KESEHATAN

Sekretariat : Lantai 3 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 294 / H4.8.4.5.31 / PP36-KOMETIK / 2018

Tanggal: 16 April 2018

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH18030174	No Sponsor Protokol	
Peneliti Utama	**dr. Wenny Yaury**	Sponsor	**Pribadi**
Judul Peneliti	Korelasi Antara Nefrinuria dan Preeklampsia Berat		
No Versi Protokol	**1**	Tanggal Versi	**23 Maret 2018**
No Versi PSP	**1**	Tanggal Versi	**23 Maret 2018**
Tempat Penelitian	**RSUP dr. Wahidin Sudirohusodo dan RS Jejaring di Makassar**		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **16 April 2018** sampai **16 April 2019**	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	Tanggal
Sekretaris Komisi Etik Penelitian	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	Tanggal

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 5

RUMAH SAKIT UNIVERSITAS HASANUDDIN	SURAT IZIN PENELITIAN	
	Nomor: 4865 /UN4.26.1.2/PL.02/2018	Tanggal 07 Agustus 2018
FORMULIR 2 BIDANG PENDIDIKAN DAN PENELITIAN	Kepada Yth **Kepala Instalasi Rawat Inap dan Kamar Bersalin**	

Dengan hormat,

Dengan ini menerangkan bahwa peneliti/ mahasiswa berikut ini:

Nama	: dr. Wenny Yaury
NIM / NIP	: C105215203
Institusi	: Pendidikan dokter spesialis (Sp-1), Fakultas Kedokteran, Universitas Hasanuddin
Kode peneliti	: 180801_1

Akan melakukan pengambilan data/ analisa bahan hayati:

Terhitung	: 01 Agustus 2018 s/d 01 November 2018
Jumlah Subjek/Sample	: 88
Jenis Data	: uji laboratorium ELISA nephrinuria (urin ibu hamil), rekam medis (identitas dan hasil lab.lainnya)

Untuk penelitian dengan judul:

"Korelasi antara Nephrinuria dan Preeklampsia berat"

Harap dilakukan pembimbingan dan pendampingan seperlunya.

Kepala Bidang Penelitian

dr. Firdaus, PhD
NIP.197712312002121002

Catatan: Lembaran ini diarsipkan oleh Bidang Penelitian dan Inovasi

Lampiran 6

RUMAH SAKIT UNIVERSITAS HASANUDDIN	SURAT KETERANGAN SEMENTARA SELESAI PENGAMBILAN DATA/ ANALISA BAHAN HAYATI
	Diterbitkan oleh Laboratorium Penelitian
FORMULIR 3 BIDANG PENDIDIKAN DAN PENELITIAN	Ditujukan Kepada KEPALA BIDANG PENDIDIKAN DAN PENELITIAN

Dengan hormat,

Dengan ini menerangkan bahwa peneliti/ mahasiswa berikut ini

Nama	: dr. Wenny Yaury
NIM / NIP	: C 105215203
Institusi	: Universitas Hasanuddin, Fakultas Kedokteran, Sp-1
	(Untuk mahasiswa: Nama institusi, fakultas, program studi)
Kode peneliti	: 180801_1

TELAH SELESAI melakukan pengambilan data:

Pada tanggal	: 06 Maret 2019
Jumlah subjek	: 90 sampel
Jenis data	: Data primer pemeriksaan menggunakan Elisa Reader
Dengan nama pendamping/ pembimbing	
Staff	: Sulhidaya, S.T
Konsultan	: dr. Muh. Firdaus Kasim, M.Sc

Surat keterangan ini juga merupakan penjelasan bahwa peneliti/mahasiswa di atas tidak mempunyai sangkutan lagi pada unit/ instalasi kami

Kepala Ruang

dr. Muh. Firdaus Kasim, M.Sc
NIP. 19841201201807300 1

Catatan: lembaran ini diberikan kepada mahasiswa/peneliti untuk diserahkan kepada Bidang Pendidikan dan Penelitian setelah pengambilan data / analisa bahan hayati selesai

Lampiran 7

Bioassay Technology Laboratory

Optimize Your Research

Human Nephrin ELISA Kit

USER INSTRUCTION

Cat.No E1091Hu

Standard Curve Range: 0.1ng/ml - 40ng/ml

Sensitivity: 0.04ng/ml

Size: 96 wells

Storage: Store the reagents at 2-8°C. For long term storage refer to the expiration date keep it at -20°C. Avoid repeated thaw cycles. If individual reagents are opened it is recommended that the kit be used within 1 month.

**This product is for research use only, not for use in diagnosis procedures. It's highly recommend to read this instruction entirely before the use.*

PRECISION

Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision.

CV(%) = SD/mean x 100

Intra-Assay: CV<8%

Inter-Assay: CV<10%

INTENDED USE

This sandwich kit is for the accurate quantitative detection of human Nephrin (also known as NPHN) in serum, plasma, cell culture supernates, cell lysates, tissue homogenates.

ASSAY PRINCIPLE

This kit is a Enzyme-Linked Immunosorbent Assay (ELISA). NPHN is added to the wells pre-coated with NPHN monoclonal antibody. After cubation a biotin-conjugated anti-human NPHN antibody is added and binds to human NPHN. After incubation unbound biotin-conjugated

www.bt-laboratory.com | 1713 Junjiang International Bldg. 218Ningguo Rd. Yangpu Dist. Shanghai.China
Tel: 86 21 65109711 | Fax: 86 21 65109711 816 | E-mail: save@bt-laboratory.com

anti-human NPHN antibody is washed away during a washing step. Streptavidin-HRP is added and binds to the biotin-conjugated anti-human NPHN antibody. After incubation unbound Streptavidin-HRP is washed away during a washing step. Substrate solution is then added and color develops in proportion to the amount of human NPHN. The reaction is terminated by addition of acidic stop solution and absorbance is measured at 450 nm.

REAGENT PROVIDED

Components	Quantity
Standard Solution (48ng/ml)	0.5ml x1
Pre-coated ELISA Plate	12 * 8 well strips x1
Standard Diluent	3ml x1
Streptavidin-HRP	6ml x1
Stop Solution	6ml x1
Substrate Solution A	6ml x1
Substrate Solution B	6ml x1
Wash Buffer Concentrate (30x)	20ml x1
Biotin-Conjugate Anti-human NPHN Antibody	1ml x1
User Instruction	1
Plate Sealer	2 pics
Zipper bag	1

MATERIALS REQUIRED BUT NOT SUPPLIED

- 37°C±0.5°C incubator
- Absorbent paper
- Precision pipettes and disposable pipette tips
- Clean tubes
- Deionized or distilled water
- Microplate reader with 450 ± 10nm wavelength filter

PRECAUTIONS

- Prior to use, the kit and sample should be warmed naturally to room temperature 30 minutes.
- Once the desired number of strips has been removed, immediately reseal the bag to protect the remain from deterioration. Cover all reagents when not in use.
- Make sure pipetting order and rate of addition from well-to-well when pipetting reagents.
- This instruction must be strictly followed in the experiment.

- Pipette tips and plate sealer in hand should be clean and disposable to avoid cross-contamination.
- Avoid using the reagents from different batches together.
- Substrate solution B is sensitive to light, don't expose substrate solution B to light for a long time.
- Stop solution contains acid. Please wear eye, hand and skin protection when using this material. Avoid contact of skin or mucous membranes with kit reagent.
- The kit should not be used beyond the expiration date.

SPECIMEN COLLECTION

Serum Allow serum to clot for 10-20 minutes at room temperature. Centrifuge at 2000-3000 RPM for 20 minutes.

Plasma Collect plasma using EDTA or heparin as an anticoagulant. Centrifuge samples for 15 minutes at 2000-3000 RPM at 2 - 8°C within 30 minutes of collection.

Urine Collect by sterile tube. Centrifuge at 2000-3000 RPM for approximately 20 minutes. When collecting pleuroperitoneal fluid and cerebrospinal fluid, please follow the procedures above-mentioned.

Cell culture supernatant Collect by sterile tubes when examining secrete components. Centrifuge at 2000-3000 RPM for approximately 20 minutes. Collect the supernatants carefully. When examining the components within the cell, use PBS (pH 7.2-7.4) to dilute cell suspension to the cell concentration of approximately 1 million/ml. Damage cells through repeated freeze-thaw cycles to let out the inside components. Centrifuge at 2000-3000 RPM for approximately 20 minutes.

Tissue Rinse tissues in PBS (pH 7.4) to remove excess blood thoroughly and weigh before homogenization. Mince tissues and homogenize them in PBS (pH7.4) with a glass homogenizer on ice. Thaw at 2-8°C or freeze at -20°C. Centrifuge at 2000-3000 RPM for approximately 20 minutes.

Note

- Sample concentrations should be predicted before being used in the assay. If the sample concentration is not within the range of the standard curve, users must **contact us** to determine the optimal sample for their particular experiments.
- Samples to be used within 5 days should be stored at 2-8°C. Samples should be aliquoted or

must be stored at -20°C within 1 month or -80°C within 6 months. Avoid repeated freeze thaw cycles.

- Samples should be brought to room temperature before starting the assay.
- Samples containing NaN3 can't be tested as it inhibits the activity of Horse Radish Peroxidase (HRP).
- Collect the supernatants carefully. When sediments occurred during storage, centrifugation should be performed again.
- Hemolysis can greatly impact the validity of test results. Take care to minimize hemolysis.

SAMPLE CAN'T BE DILUTED WITH THIS KIT. ONCE THE SAMPLE HAS BEEN DILUTED IT WILL RESULT IN HIGH BACKGROUND!

REAGENTS PREPARATION

- All reagents should be brought to room temperature before use.
- **Standard** Reconstitute the 120μl of the standard (48ng/ml) with 120μl of standard diluent to generate a 24ng/ml standard stock solution. Allow the standard to sit for 15 mins with gentle agitation prior to making dilutions. Prepare duplicate standard points by serially diluting the standard stock solution (24ng/ml) 1:2 with standard diluent to produce 12ng/ml, 6ng/ml, 3ng/ml and 1.5ng/ml solutions. Standard diluent serves as the zero standard(0 ng/ml). Any remaining solution should be frozen at -20°C and used within one month. Dilution of standard solutions suggested are as follows:

24ng/ml	Standard No.5	120μl Original Standard + 120μl Standard Diluent
12ng/ml	Standard No.4	120μl Standard No.5 + 120μl Standard Diluent
6ng/ml	Standard No.3	120μl Standard No.4 + 120μl Standard Diluent
3ng/ml	Standard No.2	120μl Standard No.3 + 120μl Standard Diluent
1.5ng/ml	Standard No.1	120μl Standard No.2 + 120μl Standard Diluent



Standard Concentration	Standard No.5	Standard No.4	Standard No.3	Standard No.2	Standard No.1
48ng/ml	24ng/ml	12ng/ml	6ng/ml	3ng/ml	1.5ng/ml

- **Wash Buffer** Dilute 20ml of Wash Buffer Concentrate 30x into deionized or distilled water to yield 500 ml of 1x Wash Buffer. If crystals have formed in the concentrate, mix gently until the crystals have completely dissolved.

ASSAY PROCEDURE

1. Prepare all reagents, standard solutions and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature.
2. Determine the number of strips required for the assay. Insert the strips in the frames for use. The unused strips should be stored at 2-8°C.
3. Add 50µl standard to standard well.
4. Add 40µl sample to sample wells and then add 10µl anti-NPHN antibody to sample wells, then add 50µl streptavidin-HRP to sample wells and standard wells (Not blank control well) . Mix well. Cover the plate with a sealer. Incubate 60 minutes at 37°C.
5. Remove the sealer and wash the plate 5 times with wash buffer. Soak wells with at least 0.35 ml wash buffer for 30 seconds to 1 minute for each wash. For automated washing, aspirate all wells and wash 5 times with wash buffer, overfilling wells with wash buffer. Blot the plate onto paper towels or other absorbent material.
6. Add 50µl substrate solution A to each well and then add 50µl substrate solution B to each well. Incubate plate covered with a new sealer for 10 minutes at 37°C in the dark.
7. Add 50µl Stop Solution to each well, the blue color will change into yellow immediately.
8. Determine the optical density (OD value) of each well immediately using a microplate reader set to 450 nm within 30 min after adding the stop solution.

SUMMARY

Prepare all reagents, samples and standards.

Add samples, standards and ELISA solutions. Incubate for 1 hour at 37°C.

Wash the plate 5 times.

Add substrate solution A and B. Incubate for 10 minutes at 37°C for color development.

Add stop solution.

Read the OD value within 10 minutes.

Calculate.

CALCULATION OF RESULTS

Construct a standard curve by plotting the average OD for each standard on the vertical (Y) axis against the concentration on the horizontal (X) axis and draw a best fit curve through the points on the graph. These calculations can be best performed with computer-based curve-fitting software and the best fit line can be determined by regression analysis. If the standard have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

TYPICAL DATA

This standard curve is only for demonstration purposes. A standard curve should be generated with each assay.



TROUBLESHOOTING

Possible Case	Solution
High Background	
• Improper washing • Substrate was contaminated • Non-specific binding of antibody • Plate are not be sealing incompletely • Incorrect incubation temperature • Substrate exposed to light prior to use • Contaminated wash buffer	• Increasing duration of soaking steps • Replace. Substrate should be clean and avoid crossed contamination by using the sealer • Replace another purified antibody or blocking buffer • Make sure to follow the instruction strictly • Incubate at room temperature • Keep substrate in a dark place • Use a clean buffers and sterile filter
Weak Signal	
• Improper washing • Incorrect incubation temperature • Antibody are not enough • Reagent are contaminated • Pipette are not clean	• Increasing duration of soaking steps • Incubate at room temperature • Increase the concentration of the antibody • Use new one • Pipette should be clean
No Signal	
• Reagent are contaminated • Sample prepared incorrectly • Antibody are not enough • Wash buffer contains sodium azide • HRP was not added	• Use new one • Make sure the sample workable/dilution • Increase the antibody concentration • Use a new wash buffer and avoid sodium azide in it • Add HRP according to the instruction
Poor Standard Curve	
• Improper standard dilution • Inccorect storage of reagents • Incomplete washing of the wells • Capture antibody did not bind to the plate	• Reconstitute standard according to the instruction • Store the reagents in the ELISA kit according to the printed instruction before using them • Make sure wells are washed adequately by filling the wells with wash buffer and all residual antibody solutions crossed well before washing. • Replace a new ELISA plate

DATA TEMPLATE

	1	2	3	4	5	6	7	8	9	10	11	12
A												
B												
C												
D												
E												
F												
G												
H												

If you have any question on the order please contact us via: order @bt-laboratory.com;
If you need any technical assistance please contact us via: support@bt-laboratory.com.

www.bt-laboratory.com | 1713 Junjiang International Bldg. 218Ningguo Rd. Yangpu Dist. Shanghai.China
Tel: 86 21 65109711 | Fax: 86 21 65109711 816 | E-mail: save@bt-laboratory.com

Lampiran 8

QuantitativeCurveFit1

Parameters

Fit to	Assay: Calibrator
Fit type	Four Parameter Logistic
Concentration transform	Linear
Measurement transform	Linear
Markers	Mean
Formula	y = d + (a - d)/(1 + (x / c)^b)
Parameter a	-0.0059
Parameter b	0.8872
Parameter c	413.0318
Parameter d	9.5743
Coefficient of determination R2	0.9969

Plate	Well	Sample	Conc.	Original [A	Fitted [Abs	Residual
		Cal_0001	24.0000	0.7024	0.7045	-0.0021
Plate 1	A01	Cal_0001	24.0000	0.7024	0.7045	-0.0021
		Cal_0002	12.0000	0.3819	0.3917	-0.0098
Plate 1	B01	Cal_0002	12.0000	0.3819	0.3917	-0.0098
		Cal_0003	6.0000	0.2163	0.2133	0.0030
Plate 1	C01	Cal_0003	6.0000	0.2163	0.2133	0.0030
		Cal_0004	3.0000	0.1197	0.1138	0.0059
Plate 1	D01	Cal_0004	3.0000	0.1197	0.1138	0.0059
		Cal_0005	1.5000	0.0524	0.0592	-0.0068
Plate 1	E01	Cal_0005	1.5000	0.0524	0.0592	-0.0068

Plate 1: Plate 1

Abs	1	2	3	4	5	6	7	8	9	10	11	12
A	0.7024	0.4027	0.4238	0.8234	0.4642	0.2993	0.3136	0.2530	0.3128	0.5811	0.5115	0.2500
B	0.3819	0.2544	0.3628	0.3593	0.4181	0.3545	0.2463	0.3181	0.2732	0.3674	0.4230	0.5413
C	0.2163	0.3153	0.3425	0.4122	0.4034	0.4099	1.1605	0.4030	0.4280	0.3023	0.3177	0.3486
D	0.1197	0.4091	0.2831	0.5490	0.3760	0.3655	0.4178	0.1354	0.4693	0.1556	0.4055	0.3563
E	0.0524	0.3378	0.3361	0.4775	0.3269	0.3577	0.2734	0.3874	0.4653	0.3150	0.5697	0.4338
F		0.4451	0.3489	0.5643	0.3655	0.1769	0.3167	0.3093	0.4011	0.4164	0.5018	0.5140
G	0.2356	0.4318	0.4575	0.5973	0.2102	0.2281	0.1591	0.2962	0.3707	0.2361	0.3640	0.5104
H	0.2929	0.5008	0.4615	0.5121	0.2697	0.6295	0.3393	0.5858	0.3678	0.4482	1.2380	0.2821

Fitted conc	1	2	3	4	5	6	7	8	9	10	11	12
A		12.3899	13.1474	NaN	14.6215	8.8056	9.2882	7.2743	9.2611	19.0556	16.3858	7.1768
B		7.3199	10.9811	10.8590	12.9419	10.6920	7.0567	9.4409	7.9365	11.1419	13.1186	17.5183
C		9.3458	10.2765	12.7299	12.4149	12.6474	NaN	12.4006	13.2992	8.9065	9.4273	10.4874
D		12.6188	8.2644	17.8135	11.4437	11.0754	12.9311	3.6245	14.8098	4.2238	12.4899	10.7546
E		10.1146	10.0562	15.1135	9.7408	10.8033	7.9431	11.8460	14.6621	9.3356	18.6124	13.5094
F		13.9208	10.4978	18.4032	11.0754	4.8691	9.3933	9.1426	12.3328	12.8808	16.0207	16.4802
G	6.7116	13.4369	14.3749	19.6893	5.9033	6.4712	4.3289	8.7016	11.2575	6.7276	11.0230	16.3444
H	8.5911	15.9831	14.5220	16.4085	7.8211	20.9627	10.1662	19.2389	11.1559	14.0340	NaN	8.2311

Sample	1	2	3	4	5	6	7	8	9	10	11	12
A	Cal_0001	Un_0003 1	Un_0011 1	Un_0019 1	Un_0027 1	Un_0035 1	Un_0043 1	Un_0051 1	Un_0059 1	Un_0067 1	Un_0075 1	Un_0083 1
B	Cal_0002	Un_0004 1	Un_0012 1	Un_0020 1	Un_0028 1	Un_0036 1	Un_0044 1	Un_0052 1	Un_0060 1	Un_0068 1	Un_0076 1	Un_0084 1
C	Cal_0003	Un_0005 1	Un_0013 1	Un_0021 1	Un_0029 1	Un_0037 1	Un_0045 1	Un_0053 1	Un_0061 1	Un_0069 1	Un_0077 1	Un_0085 1
D	Cal_0004	Un_0006 1	Un_0014 1	Un_0022 1	Un_0030 1	Un_0038 1	Un_0046 1	Un_0054 1	Un_0062 1	Un_0070 1	Un_0078 1	Un_0086 1
E	Cal_0005	Un_0007 1	Un_0015 1	Un_0023 1	Un_0031 1	Un_0039 1	Un_0047 1	Un_0055 1	Un_0063 1	Un_0071 1	Un_0079 1	Un_0087 1
F		Un_0008 1	Un_0016 1	Un_0024 1	Un_0032 1	Un_0040 1	Un_0048 1	Un_0056 1	Un_0064 1	Un_0072 1	Un_0080 1	Un_0088 1
G	Un_0001 1	Un_0009 1	Un_0017 1	Un_0025 1	Un_0033 1	Un_0041 1	Un_0049 1	Un_0057 1	Un_0065 1	Un_0073 1	Un_0081 1	Un_0089 1
H	Un_0002 1	Un_0010 1	Un_0018 1	Un_0026 1	Un_0034 1	Un_0042 1	Un_0050 1	Un_0058 1	Un_0066 1	Un_0074 1	Un_0082 1	Un_0090 1

Dilution	1	2	3	4	5	6	7	8	9	10	11	12
A	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	
B	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	
C	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	
D	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	
E	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	

	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1
1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1
1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1

sult	1	2	3	4	5	6	7	8	9	10	11	12
		12.3899	13.1474	NaN	14.6215	8.8056	9.2882	7.2743	9.2611	19.0556	16.3858	7.1768
		7.3199	10.9811	10.8590	12.9419	10.6920	7.0567	9.4409	7.9365	11.1419	13.1186	17.5183
		9.3458	10.2765	12.7299	12.4149	12.6474	NaN	12.4006	13.2992	8.9065	9.4273	10.4874
		12.6188	8.2644	17.8135	11.4437	11.0754	12.9311	3.6245	14.8098	4.2238	12.4899	10.7546
		10.1146	10.0562	15.1135	9.7408	10.8033	7.9431	11.8460	14.6621	9.3356	18.6124	13.5094
		13.9208	10.4978	18.4032	11.0754	4.8691	9.3933	9.1426	12.3328	12.8808	16.0207	16.4802
	6.7116	13.4369	14.3749	19.6893	5.9033	6.4712	4.3289	8.7016	11.2575	6.7276	11.0230	16.3444
	8.5911	15.9831	14.5220	16.4085	7.8211	20.9627	10.1662	19.2389	11.1559	14.0340	NaN	8.2311

QuantitativeCurveFit1

Plate	Well	Group	Type	Sample	Original [At	Fitted conc	Dilution	Result	SD	CV%	Meas. Time
		Assay	Unknown	Un_0001	0.2356	6.7116	1.0000	6.7116	NaN	NaN	0.0000
Plate 1	G01	Assay	Unknown	Un_0001 1	0.2356	6.7116	1.0000	6.7116	NaN	NaN	3.7200
		Assay	Unknown	Un_0002	0.2929	8.5911	1.0000	8.5911	NaN	NaN	0.0000
Plate 1	H01	Assay	Unknown	Un_0002 1	0.2929	8.5911	1.0000	8.5911	NaN	NaN	4.5000
		Assay	Unknown	Un_0003	0.4027	12.3899	1.0000	12.3899	NaN	NaN	0.0000
Plate 1	A02	Assay	Unknown	Un_0003 1	0.4027	12.3899	1.0000	12.3899	NaN	NaN	0.0200
		Assay	Unknown	Un_0004	0.2544	7.3199	1.0000	7.3199	NaN	NaN	0.0000
Plate 1	B02	Assay	Unknown	Un_0004 1	0.2544	7.3199	1.0000	7.3199	NaN	NaN	0.7700
		Assay	Unknown	Un_0005	0.3153	9.3458	1.0000	9.3458	NaN	NaN	0.0000
Plate 1	C02	Assay	Unknown	Un_0005 1	0.3153	9.3458	1.0000	9.3458	NaN	NaN	1.2600
		Assay	Unknown	Un_0006	0.4091	12.6188	1.0000	12.6188	NaN	NaN	0.0000
Plate 1	D02	Assay	Unknown	Un_0006 1	0.4091	12.6188	1.0000	12.6188	NaN	NaN	2.0100
		Assay	Unknown	Un_0007	0.3378	10.1146	1.0000	10.1146	NaN	NaN	0.0000
Plate 1	E02	Assay	Unknown	Un_0007 1	0.3378	10.1146	1.0000	10.1146	NaN	NaN	2.5000
		Assay	Unknown	Un_0008	0.4451	13.9208	1.0000	13.9208	NaN	NaN	0.0000
Plate 1	F02	Assay	Unknown	Un_0008 1	0.4451	13.9208	1.0000	13.9208	NaN	NaN	3.2500
		Assay	Unknown	Un_0009	0.4318	13.4369	1.0000	13.4369	NaN	NaN	0.0000
Plate 1	G02	Assay	Unknown	Un_0009 1	0.4318	13.4369	1.0000	13.4369	NaN	NaN	3.7300
		Assay	Unknown	Un_0010	0.5008	15.9831	1.0000	15.9831	NaN	NaN	0.0000
Plate 1	H02	Assay	Unknown	Un_0010 1	0.5008	15.9831	1.0000	15.9831	NaN	NaN	4.4800
		Assay	Unknown	Un_0011	0.4238	13.1474	1.0000	13.1474	NaN	NaN	0.0000
Plate 1	A03	Assay	Unknown	Un_0011 1	0.4238	13.1474	1.0000	13.1474	NaN	NaN	0.0400
		Assay	Unknown	Un_0012	0.3628	10.9811	1.0000	10.9811	NaN	NaN	0.0000
Plate 1	B03	Assay	Unknown	Un_0012 1	0.3628	10.9811	1.0000	10.9811	NaN	NaN	0.7500
		Assay	Unknown	Un_0013	0.3425	10.2765	1.0000	10.2765	NaN	NaN	0.0000
Plate 1	C03	Assay	Unknown	Un_0013 1	0.3425	10.2765	1.0000	10.2765	NaN	NaN	1.2800
		Assay	Unknown	Un_0014	0.2831	8.2644	1.0000	8.2644	NaN	NaN	0.0000
Plate 1	D03	Assay	Unknown	Un_0014 1	0.2831	8.2644	1.0000	8.2644	NaN	NaN	1.9900
		Assay	Unknown	Un_0015	0.3361	10.0562	1.0000	10.0562	NaN	NaN	0.0000
Plate 1	E03	Assay	Unknown	Un_0015 1	0.3361	10.0562	1.0000	10.0562	NaN	NaN	2.5200
		Assay	Unknown	Un_0016	0.3489	10.4978	1.0000	10.4978	NaN	NaN	0.0000
Plate 1	F03	Assay	Unknown	Un_0016 1	0.3489	10.4978	1.0000	10.4978	NaN	NaN	3.2300
		Assay	Unknown	Un_0017	0.4575	14.3749	1.0000	14.3749	NaN	NaN	0.0000
Plate 1	G03	Assay	Unknown	Un_0017 1	0.4575	14.3749	1.0000	14.3749	NaN	NaN	3.7500
		Assay	Unknown	Un_0018	0.4615	14.5220	1.0000	14.5220	NaN	NaN	0.0000
Plate 1	H03	Assay	Unknown	Un_0018 1	0.4615	14.5220	1.0000	14.5220	NaN	NaN	4.4600
		Assay	Unknown	Un_0019	0.8234	NaN	1.0000	NaN	NaN	NaN	0.0000
Plate 1	A04	Assay	Unknown	Un_0019 1	0.8234	NaN	1.0000	NaN	NaN	NaN	0.0600
		Assay	Unknown	Un_0020	0.3593	10.8590	1.0000	10.8590	NaN	NaN	0.0000
Plate 1	B04	Assay	Unknown	Un_0020 1	0.3593	10.8590	1.0000	10.8590	NaN	NaN	0.7300
		Assay	Unknown	Un_0021	0.4122	12.7299	1.0000	12.7299	NaN	NaN	0.0000
Plate 1	C04	Assay	Unknown	Un_0021 1	0.4122	12.7299	1.0000	12.7299	NaN	NaN	1.3000
		Assay	Unknown	Un_0022	0.5490	17.8135	1.0000	17.8135	NaN	NaN	0.0000
Plate 1	D04	Assay	Unknown	Un_0022 1	0.5490	17.8135	1.0000	17.8135	NaN	NaN	1.9700
		Assay	Unknown	Un_0023	0.4775	15.1135	1.0000	15.1135	NaN	NaN	0.0000
Plate 1	E04	Assay	Unknown	Un_0023 1	0.4775	15.1135	1.0000	15.1135	NaN	NaN	2.5300
		Assay	Unknown	Un_0024	0.5643	18.4032	1.0000	18.4032	NaN	NaN	0.0000
Plate 1	F04	Assay	Unknown	Un_0024 1	0.5643	18.4032	1.0000	18.4032	NaN	NaN	3.2100
		Assay	Unknown	Un_0025	0.5973	19.6893	1.0000	19.6893	NaN	NaN	0.0000
Plate 1	G04	Assay	Unknown	Un_0025 1	0.5973	19.6893	1.0000	19.6893	NaN	NaN	3.7700
		Assay	Unknown	Un_0026	0.5121	16.4085	1.0000	16.4085	NaN	NaN	0.0000
Plate 1	H04	Assay	Unknown	Un_0026 1	0.5121	16.4085	1.0000	16.4085	NaN	NaN	4.4500
		Assay	Unknown	Un_0027	0.4642	14.6215	1.0000	14.6215	NaN	NaN	0.0000
Plate 1	A05	Assay	Unknown	Un_0027 1	0.4642	14.6215	1.0000	14.6215	NaN	NaN	0.0800
		Assay	Unknown	Un_0028	0.4181	12.9419	1.0000	12.9419	NaN	NaN	0.0000
Plate 1	B05	Assay	Unknown	Un_0028 1	0.4181	12.9419	1.0000	12.9419	NaN	NaN	0.7100
		Assay	Unknown	Un_0029	0.4034	12.4149	1.0000	12.4149	NaN	NaN	0.0000
Plate 1	C05	Assay	Unknown	Un_0029 1	0.4034	12.4149	1.0000	12.4149	NaN	NaN	1.3100
		Assay	Unknown	Un_0030	0.3760	11.4437	1.0000	11.4437	NaN	NaN	0.0000
Plate 1	D05	Assay	Unknown	Un_0030 1	0.3760	11.4437	1.0000	11.4437	NaN	NaN	1.9500

		Assay	Unknown	Un_0031	0.3269	9.7408	1.0000	9.7408	NaN	NaN	0.0000
Plate 1	E05	Assay	Unknown	Un_0031 1	0.3269	9.7408	1.0000	9.7408	NaN	NaN	2.5500
		Assay	Unknown	Un_0032	0.3655	11.0754	1.0000	11.0754	NaN	NaN	0.0000
Plate 1	F05	Assay	Unknown	Un_0032 1	0.3655	11.0754	1.0000	11.0754	NaN	NaN	3.1900
		Assay	Unknown	Un_0033	0.2102	5.9033	1.0000	5.9033	NaN	NaN	0.0000
Plate 1	G05	Assay	Unknown	Un_0033 1	0.2102	5.9033	1.0000	5.9033	NaN	NaN	3.7900
		Assay	Unknown	Un_0034	0.2697	7.8211	1.0000	7.8211	NaN	NaN	0.0000
Plate 1	H05	Assay	Unknown	Un_0034 1	0.2697	7.8211	1.0000	7.8211	NaN	NaN	4.4300
		Assay	Unknown	Un_0035	0.2993	8.8056	1.0000	8.8056	NaN	NaN	0.0000
Plate 1	A06	Assay	Unknown	Un_0035 1	0.2993	8.8056	1.0000	8.8056	NaN	NaN	0.0900
		Assay	Unknown	Un_0036	0.3545	10.6920	1.0000	10.6920	NaN	NaN	0.0000
Plate 1	B06	Assay	Unknown	Un_0036 1	0.3545	10.6920	1.0000	10.6920	NaN	NaN	0.6900
		Assay	Unknown	Un_0037	0.4099	12.6474	1.0000	12.6474	NaN	NaN	0.0000
Plate 1	C06	Assay	Unknown	Un_0037 1	0.4099	12.6474	1.0000	12.6474	NaN	NaN	1.3300
		Assay	Unknown	Un_0038	0.3655	11.0754	1.0000	11.0754	NaN	NaN	0.0000
Plate 1	D06	Assay	Unknown	Un_0038 1	0.3655	11.0754	1.0000	11.0754	NaN	NaN	1.9300
		Assay	Unknown	Un_0039	0.3577	10.8033	1.0000	10.8033	NaN	NaN	0.0000
Plate 1	E06	Assay	Unknown	Un_0039 1	0.3577	10.8033	1.0000	10.8033	NaN	NaN	2.5700
		Assay	Unknown	Un_0040	0.1769	4.8691	1.0000	4.8691	NaN	NaN	0.0000
Plate 1	F06	Assay	Unknown	Un_0040 1	0.1769	4.8691	1.0000	4.8691	NaN	NaN	3.1700
		Assay	Unknown	Un_0041	0.2281	6.4712	1.0000	6.4712	NaN	NaN	0.0000
Plate 1	G06	Assay	Unknown	Un_0041 1	0.2281	6.4712	1.0000	6.4712	NaN	NaN	3.8100
		Assay	Unknown	Un_0042	0.6295	20.9627	1.0000	20.9627	NaN	NaN	0.0000
Plate 1	H06	Assay	Unknown	Un_0042 1	0.6295	20.9627	1.0000	20.9627	NaN	NaN	4.4100
		Assay	Unknown	Un_0043	0.3136	9.2882	1.0000	9.2882	NaN	NaN	0.0000
Plate 1	A07	Assay	Unknown	Un_0043 1	0.3136	9.2882	1.0000	9.2882	NaN	NaN	0.1100
		Assay	Unknown	Un_0044	0.2463	7.0567	1.0000	7.0567	NaN	NaN	0.0000
Plate 1	B07	Assay	Unknown	Un_0044 1	0.2463	7.0567	1.0000	7.0567	NaN	NaN	0.6700
		Assay	Unknown	Un_0045	1.1605	NaN	1.0000	NaN	NaN	NaN	0.0000
Plate 1	C07	Assay	Unknown	Un_0045 1	1.1605	NaN	1.0000	NaN	NaN	NaN	1.3500
		Assay	Unknown	Un_0046	0.4178	12.9311	1.0000	12.9311	NaN	NaN	0.0000
Plate 1	D07	Assay	Unknown	Un_0046 1	0.4178	12.9311	1.0000	12.9311	NaN	NaN	1.9100
		Assay	Unknown	Un_0047	0.2734	7.9431	1.0000	7.9431	NaN	NaN	0.0000
Plate 1	E07	Assay	Unknown	Un_0047 1	0.2734	7.9431	1.0000	7.9431	NaN	NaN	2.5900
		Assay	Unknown	Un_0048	0.3167	9.3933	1.0000	9.3933	NaN	NaN	0.0000
Plate 1	F07	Assay	Unknown	Un_0048 1	0.3167	9.3933	1.0000	9.3933	NaN	NaN	3.1500
		Assay	Unknown	Un_0049	0.1591	4.3289	1.0000	4.3289	NaN	NaN	0.0000
Plate 1	G07	Assay	Unknown	Un_0049 1	0.1591	4.3289	1.0000	4.3289	NaN	NaN	3.8300
		Assay	Unknown	Un_0050	0.3393	10.1662	1.0000	10.1662	NaN	NaN	0.0000
Plate 1	H07	Assay	Unknown	Un_0050 1	0.3393	10.1662	1.0000	10.1662	NaN	NaN	4.3900
		Assay	Unknown	Un_0051	0.2530	7.2743	1.0000	7.2743	NaN	NaN	0.0000
Plate 1	A08	Assay	Unknown	Un_0051 1	0.2530	7.2743	1.0000	7.2743	NaN	NaN	0.1300
		Assay	Unknown	Un_0052	0.3181	9.4409	1.0000	9.4409	NaN	NaN	0.0000
Plate 1	B08	Assay	Unknown	Un_0052 1	0.3181	9.4409	1.0000	9.4409	NaN	NaN	0.6500
		Assay	Unknown	Un_0053	0.4030	12.4006	1.0000	12.4006	NaN	NaN	0.0000
Plate 1	C08	Assay	Unknown	Un_0053 1	0.4030	12.4006	1.0000	12.4006	NaN	NaN	1.3700
		Assay	Unknown	Un_0054	0.1354	3.6245	1.0000	3.6245	NaN	NaN	0.0000
Plate 1	D08	Assay	Unknown	Un_0054 1	0.1354	3.6245	1.0000	3.6245	NaN	NaN	1.8900
		Assay	Unknown	Un_0055	0.3874	11.8460	1.0000	11.8460	NaN	NaN	0.0000
Plate 1	E08	Assay	Unknown	Un_0055 1	0.3874	11.8460	1.0000	11.8460	NaN	NaN	2.6100
		Assay	Unknown	Un_0056	0.3093	9.1426	1.0000	9.1426	NaN	NaN	0.0000
Plate 1	F08	Assay	Unknown	Un_0056 1	0.3093	9.1426	1.0000	9.1426	NaN	NaN	3.1300
		Assay	Unknown	Un_0057	0.2962	8.7016	1.0000	8.7016	NaN	NaN	0.0000
Plate 1	G08	Assay	Unknown	Un_0057 1	0.2962	8.7016	1.0000	8.7016	NaN	NaN	3.8500
		Assay	Unknown	Un_0058	0.5858	19.2389	1.0000	19.2389	NaN	NaN	0.0000
Plate 1	H08	Assay	Unknown	Un_0058 1	0.5858	19.2389	1.0000	19.2389	NaN	NaN	4.3700
		Assay	Unknown	Un_0059	0.3128	9.2611	1.0000	9.2611	NaN	NaN	0.0000
Plate 1	A09	Assay	Unknown	Un_0059 1	0.3128	9.2611	1.0000	9.2611	NaN	NaN	0.1500
		Assay	Unknown	Un_0060	0.2732	7.9365	1.0000	7.9365	NaN	NaN	0.0000
Plate 1	B09	Assay	Unknown	Un_0060 1	0.2732	7.9365	1.0000	7.9365	NaN	NaN	0.6300
		Assay	Unknown	Un_0061	0.4280	13.2992	1.0000	13.2992	NaN	NaN	0.0000
Plate 1	C09	Assay	Unknown	Un_0061 1	0.4280	13.2992	1.0000	13.2992	NaN	NaN	1.3900
		Assay	Unknown	Un_0062	0.4693	14.8098	1.0000	14.8098	NaN	NaN	0.0000

Plate 1	D09	Assay	Unknown	Un_0062 1	0.4693	14.8098	1.0000	14.8098	NaN	NaN	1.8700
		Assay	Unknown	Un_0063	0.4653	14.6621	1.0000	14.6621	NaN	NaN	0.0000
Plate 1	E09	Assay	Unknown	Un_0063 1	0.4653	14.6621	1.0000	14.6621	NaN	NaN	2.6300
		Assay	Unknown	Un_0064	0.4011	12.3328	1.0000	12.3328	NaN	NaN	0.0000
Plate 1	F09	Assay	Unknown	Un_0064 1	0.4011	12.3328	1.0000	12.3328	NaN	NaN	3.1100
		Assay	Unknown	Un_0065	0.3707	11.2575	1.0000	11.2575	NaN	NaN	0.0000
Plate 1	G09	Assay	Unknown	Un_0065 1	0.3707	11.2575	1.0000	11.2575	NaN	NaN	3.8700
		Assay	Unknown	Un_0066	0.3678	11.1559	1.0000	11.1559	NaN	NaN	0.0000
Plate 1	H09	Assay	Unknown	Un_0066 1	0.3678	11.1559	1.0000	11.1559	NaN	NaN	4.3500
		Assay	Unknown	Un_0067	0.5811	19.0556	1.0000	19.0556	NaN	NaN	0.0000
Plate 1	A10	Assay	Unknown	Un_0067 1	0.5811	19.0556	1.0000	19.0556	NaN	NaN	0.1700
		Assay	Unknown	Un_0068	0.3674	11.1419	1.0000	11.1419	NaN	NaN	0.0000
Plate 1	B10	Assay	Unknown	Un_0068 1	0.3674	11.1419	1.0000	11.1419	NaN	NaN	0.6100
		Assay	Unknown	Un_0069	0.3023	8.9065	1.0000	8.9065	NaN	NaN	0.0000
Plate 1	C10	Assay	Unknown	Un_0069 1	0.3023	8.9065	1.0000	8.9065	NaN	NaN	1.4100
		Assay	Unknown	Un_0070	0.1556	4.2238	1.0000	4.2238	NaN	NaN	0.0000
Plate 1	D10	Assay	Unknown	Un_0070 1	0.1556	4.2238	1.0000	4.2238	NaN	NaN	1.8500
		Assay	Unknown	Un_0071	0.3150	9.3356	1.0000	9.3356	NaN	NaN	0.0000
Plate 1	E10	Assay	Unknown	Un_0071 1	0.3150	9.3356	1.0000	9.3356	NaN	NaN	2.6500
		Assay	Unknown	Un_0072	0.4164	12.8808	1.0000	12.8808	NaN	NaN	0.0000
Plate 1	F10	Assay	Unknown	Un_0072 1	0.4164	12.8808	1.0000	12.8808	NaN	NaN	3.0900
		Assay	Unknown	Un_0073	0.2361	6.7276	1.0000	6.7276	NaN	NaN	0.0000
Plate 1	G10	Assay	Unknown	Un_0073 1	0.2361	6.7276	1.0000	6.7276	NaN	NaN	3.8900
		Assay	Unknown	Un_0074	0.4482	14.0340	1.0000	14.0340	NaN	NaN	0.0000
Plate 1	H10	Assay	Unknown	Un_0074 1	0.4482	14.0340	1.0000	14.0340	NaN	NaN	4.3300
		Assay	Unknown	Un_0075	0.5115	16.3858	1.0000	16.3858	NaN	NaN	0.0000
Plate 1	A11	Assay	Unknown	Un_0075 1	0.5115	16.3858	1.0000	16.3858	NaN	NaN	0.1900
		Assay	Unknown	Un_0076	0.4230	13.1186	1.0000	13.1186	NaN	NaN	0.0000
Plate 1	B11	Assay	Unknown	Un_0076 1	0.4230	13.1186	1.0000	13.1186	NaN	NaN	0.5900
		Assay	Unknown	Un_0077	0.3177	9.4273	1.0000	9.4273	NaN	NaN	0.0000
Plate 1	C11	Assay	Unknown	Un_0077 1	0.3177	9.4273	1.0000	9.4273	NaN	NaN	1.4300
		Assay	Unknown	Un_0078	0.4055	12.4899	1.0000	12.4899	NaN	NaN	0.0000
Plate 1	D11	Assay	Unknown	Un_0078 1	0.4055	12.4899	1.0000	12.4899	NaN	NaN	1.8300
		Assay	Unknown	Un_0079	0.5697	18.6124	1.0000	18.6124	NaN	NaN	0.0000
Plate 1	E11	Assay	Unknown	Un_0079 1	0.5697	18.6124	1.0000	18.6124	NaN	NaN	2.6700
		Assay	Unknown	Un_0080	0.5018	16.0207	1.0000	16.0207	NaN	NaN	0.0000
Plate 1	F11	Assay	Unknown	Un_0080 1	0.5018	16.0207	1.0000	16.0207	NaN	NaN	3.0700
		Assay	Unknown	Un_0081	0.3640	11.0230	1.0000	11.0230	NaN	NaN	0.0000
Plate 1	G11	Assay	Unknown	Un_0081 1	0.3640	11.0230	1.0000	11.0230	NaN	NaN	3.9100
		Assay	Unknown	Un_0082	1.2380	NaN	1.0000	NaN	NaN	NaN	0.0000
Plate 1	H11	Assay	Unknown	Un_0082 1	1.2380	NaN	1.0000	NaN	NaN	NaN	4.3100
		Assay	Unknown	Un_0083	0.2500	7.1768	1.0000	7.1768	NaN	NaN	0.0000
Plate 1	A12	Assay	Unknown	Un_0083 1	0.2500	7.1768	1.0000	7.1768	NaN	NaN	0.2100
		Assay	Unknown	Un_0084	0.5413	17.5183	1.0000	17.5183	NaN	NaN	0.0000
Plate 1	B12	Assay	Unknown	Un_0084 1	0.5413	17.5183	1.0000	17.5183	NaN	NaN	0.5800
		Assay	Unknown	Un_0085	0.3486	10.4874	1.0000	10.4874	NaN	NaN	0.0000
Plate 1	C12	Assay	Unknown	Un_0085 1	0.3486	10.4874	1.0000	10.4874	NaN	NaN	1.4500
		Assay	Unknown	Un_0086	0.3563	10.7546	1.0000	10.7546	NaN	NaN	0.0000
Plate 1	D12	Assay	Unknown	Un_0086 1	0.3563	10.7546	1.0000	10.7546	NaN	NaN	1.8200
		Assay	Unknown	Un_0087	0.4338	13.5094	1.0000	13.5094	NaN	NaN	0.0000
Plate 1	E12	Assay	Unknown	Un_0087 1	0.4338	13.5094	1.0000	13.5094	NaN	NaN	2.6900
		Assay	Unknown	Un_0088	0.5140	16.4802	1.0000	16.4802	NaN	NaN	0.0000
Plate 1	F12	Assay	Unknown	Un_0088 1	0.5140	16.4802	1.0000	16.4802	NaN	NaN	3.0500
		Assay	Unknown	Un_0089	0.5104	16.3444	1.0000	16.3444	NaN	NaN	0.0000
Plate 1	G12	Assay	Unknown	Un_0089 1	0.5104	16.3444	1.0000	16.3444	NaN	NaN	3.9300
		Assay	Unknown	Un_0090	0.2821	8.2311	1.0000	8.2311	NaN	NaN	0.0000
Plate 1	H12	Assay	Unknown	Un_0090 1	0.2821	8.2311	1.0000	8.2311	NaN	NaN	4.2900

KODE	OD = X	ng/mL = Y	
Standar 5	0.7024	24	**24.06**
Standar 4	0.3819	12	**11.71**
Standar 3	0.2163	6	**6.21**
Standar 2	0.1197	3	**3.27**
Standar 1	0.0524	1.5	**1.34**
Blank		0	
Ny Anita(PEB)	0.2356		**6.82**
Ny Martiah	0.2929		**8.68**
3	0.4027		**12.45**
4	0.2544		**7.42**
5	0.3153		**9.43**
6	0.4091		**12.67**
7	0.3378		**10.19**
8	0.4451		**13.97**
9	0.4318		**13.49**
10	0.5008		**16.03**
11	0.4238		**13.20**
12	0.3628		**11.05**
13	0.3425		**10.35**
14	0.2831		**8.36**
15	0.3361		**10.13**
16	0.3489		**10.57**
17	0.4575		**14.42**
18	0.4615		**14.57**
19	0.8234		**29.30**
20	0.3593		**10.93**
21	0.4122		**12.78**
22	0.5490		**17.87**
23	0.4775		**15.16**
24	0.5643		**18.47**
25	0.5973		**19.76**
26	0.5121		**16.46**
27	0.4642		**14.67**
28	0.4181		**13.00**
29	0.4034		**12.47**
30	0.3760		**11.51**
31	0.3269		**9.82**
32	0.3655		**11.14**
33	0.2102		**6.02**
34	0.2697		**7.92**
35	0.2993		**8.89**
36	0.3545		**10.76**
37	0.4099		**12.70**

38	0.3655		**11.14**
39	0.3577		**10.87**
40	0.1769		**4.98**
41	0.2281		**6.58**
42	0.6295		**21.05**
43	0.3136		**9.37**
44	0.2463		**7.16**
45	1.1605		**45.57**
46	0.4178		**12.98**
47	0.2734		**8.04**
48	0.3167		**9.47**
49	0.1591		**4.44**
Ny Adelia (Non PEB	0.3393		**10.24**
51	0.2530		**7.38**
52	0.3181		**9.52**
53	0.4030		**12.46**
54	0.1354		**3.73**
55	0.3874		**11.91**
56	0.3093		**9.23**
57	0.2962		**8.79**
58	0.5858		**19.31**
59	0.3128		**9.34**
60	0.2732		**8.03**
61	0.4280		**13.35**
62	0.4693		**14.86**
63	0.4653		**14.71**
64	0.4011		**12.39**
65	0.3707		**11.32**
66	0.3678		**11.22**
67	0.5811		**19.12**
68	0.3674		**11.21**
69	0.3023		**8.99**
70	0.1556		**4.34**
71	0.3150		**9.42**
72	0.4164		**12.93**
73	0.2361		**6.83**
74	0.4482		**14.08**
75	0.5115		**16.44**
76	0.4230		**13.17**
77	0.3177		**9.51**
78	0.4055		**12.55**
79	0.5697		**18.68**
80	0.5018		**16.07**
81	0.3640		**11.09**

82	1.2380		**49.66**
83	0.2500		**7.28**
84	0.5413		**17.57**
85	0.3486		**10.56**
86	0.3563		**10.82**
87	0.4338		**13.56**
88	0.5140		**16.53**
89	0.5104		**16.40**
90	0.2821		**8.32**

Quadratic Fit: y=a+bx+cx^2
Coefficient Data:
a = -0.08969
b = 26.76439
c = 10.84133



Prosedur

1. Pipet 50 µL ***Standar*** ke well standar
2. Pipet 40 µL ***Standar diluent*** ke well blank
3. Pipet 40 µL ***Sampel*** ke well sampel
4. Pipet 10 µL **antibodies** ke well sampel dan blank
5. Pipet 50 µL ***Streptavidin HRP*** ke seluruh well
6. Tutup dan inkubasi selama 1 jam pada suhu 37 °C
7. Aspirasi dan cuci menggunakan 400 µL ***Wash Buffer*** **1X** sebanyak 5 kali
8. Pipet 50 µL ***Chromogen Solution A*** ke seluruh well
9. Pipet 50 µL ***Chromogen Solution B*** ke seluruh well
10. Tutup dan inkubasi selama 10 menit pada suhu 37 °C, hindarkan cahaya
11. Pipet 50 µL ***Stop Solution*** ke seluruh well
12. Baca dan ukur menggunakan ***microplate reader*** pada panjang gelombang 450 nm

NO.	RM	NAMA	USIA IBU (tahun)	PARITAS	HPHT / usia kehamilan	Kehamilan Tunggal / Multipel	Jarak antar Kehamilan (tahun)	Indeks Massa Tubuh	TD SISTOLIK	TD DIASTOLIK	NEFRIN URIN	PROTEIN URIN (mg/dl)	Rumah sakit
1	18124980	Ny. A(PEB)	25	G1P0A0	13/01/2018 (39 minggu 5 hari)	1	0	27,3	160	100	**6.82**	2	Fatimah
2	18124311	Ny. M (PEB)	21	G1P0A0	09/01/2018 (40 minggu)	1	0	31,11	170	110	**12.5**	3	Fatimah
3	18125616	Ny. W (PEB)	30	G1P0A0	12/01/2018 (39 minggu 3 hari)	1	0	23,29	190	120	**7.42**	3	Fatimah
4	18125582	Ny. Ac (PEB)	20	G1P0A0	04/02/2018 (39 minggu 3 hari)	1	0	27,39	150	110	**9.43**	3	Fatimah
5	708223	Ny. R (PEB)	31	G1P0A0	8/2/2018 (39 minggu 3 hari)	1	0	27,4	160	90	**13.5**	3	pertiwi
6	701423	Ny. Bd (PEB)	29	G1P0A0	16/1/2018 (38 minggu 3hari)	1	0	27,3	160	110	**16**	2	bhayangkara
7	107533	Ny. Mrn (PEB)	30	G1P0A0	2/2018 (40 minggu 1 h	1	0	28,12	170	100	**13.2**	2	pertiwi
8	107732	Ny. Sc(PEB)	25	G1P0A0	2/2018 (38 minggu 3 h	1	0	28,01	170	100	**10.4**	2	pertiwi
9	865249	Ny. Ers (PEB)	33	G1P0A0	3/2018 (39 minggu 3 h	1	0	27,11	160	100	**10.6**	2	wahidin
10	108285	Ny. Mdt (PEB)	15	G1P0A0	1/2018 (40 minggu 3 h	1	0	34,54	160	100	**29.3**	3	pertiwi
11	298127	Ny. Nm (PEB)	31	G1P0A0	2/2018 (37 minggu 2 h	1	0	28,37	180	110	**10.9**	2	bhayangkara
12	299137	Ny. Mr (PEB)	30	G1P0A0	2/2018 (35 minggu 2 h	1	0	27,9	170	100	**12.8**	2	bhayangkara
13	18125655	Ny. NS (PEB)	18	G1P0A0	6/12/2017 (40 minggu	1	0	29,16	160	100	**18.5**	2	Fatimah
14	492566	Ny. Sul (PEB)	29	G1P0A0	2/2017 (39 minggu 5 h	1	0	32,07	160	110	**19.8**	3	pertiwi
15	18125691	Ny. Hj (PEB)	29	G1P0A0	/2018 (38 minggu 5 ha	1	0	28,9	170	100	**16.5**	2	Fatimah
16	81795	Ny. FW (PEB)	28	G1P0A0	2/2018 (37 minggu 6 h	1	0	28,7	160	110	**14.7**	3	khadijah
17	22269	Ny. SAw (PEB)	36	G1P0A0	8/02/2018 (36 minggu	1	0	30,42	190	120	**13**	2	khadijah
18	81869	Ny Rn (PEB)	37	G1P0A0	1/2018 (40 minggu 3 h	1	0	26,23	200	110	**12.5**	2	khadijah
19	83841	Ny. Ri (Non PEB)	22	G1P0A0	8/01/2017 (39 minggu	1	0	29,29	110	70	**8.89**	0	khadijah
20	88284	Ny. Ro (Non PEB)	19	G1P0A0	1/2018 (39 minggu 2 h	1	0	26,5	130	80	**10.8**	0	khadijah
21	612742	Ny. SG (PEB)	20	G1P0A0	2/2017 (38 minggu 5 h	1	0	33,29	160	110	**12.7**	2	pertiwi
22	107583	Ny. Sri (PEB)	31	G1P0A0	/2018 (39 minggu 3 ha	1	0	29,1	160	110	**11.1**	3	pertiwi
23	18125631	Ny. Ku (PEB)	19	G1P0A0	2/2017 (36 minggu 4 h	1	0	30	150	110	**10.9**	2	Fatimah
24	87751	Ny. Sr(Non PEB)	36	G1P0A0	1/2018 (39 minggu 2 h	1	0	36,88	130	80	**4.98**	0	khadijah
25	87047	Ny. Syi (PEB)	42	G1P0A0	2/2017 (39 minggu 1 h	1	0	25,71	160	110	**6.58**	3	khadijah
26	84423	Ny. L (PEB)	36	G1P0A0	1/2018 (39 minggu 1 h	1	0	30,15	150	110	**21.1**	3	khadijah
27	89765	Ny. Hl (PEB)	30	G1P0A0	5/01/2018 (38 minggu	1	0	28,2	150	110	**45.6**	3	khadijah
28	86631	Ny. W (PEB)	31	G1P0A0	4/02/2018 (39 minggu	1	0	27,92	160	110	**13**	3	khadijah
29	782622	Ny.Ku (PEB)	22	G1P0A0	1/2018 (39 minggu 2 h	1	0	33,33	160	110	**8.04**	2	pertiwi
30	18129095	Ny.K (PEB)	25	G1P0A0	2/2017 (40 minggu 5 h	1	0	31,25	150	110	**9.47**	2	Fatimah
31	16798	Ny.In (Non PEB)	20	G1P0A0	0/01/2018 (39 minggu	1	0	27,4	130	90	**4.44**	0	Fatimah
32	301245	Ny. Ad(Non PEB)	21	G1P0A0	1/2018 (39 minggu 6 h	1	0	30,83	130	90	**10.2**	0	bhayangkara
33	300865	Ny. Ri (Non PEB)	27	G1P0A0	2/2018 (37 minggu 4 h	1	0	30,10	110	70	**7.38**	0	bhayangkara
34	300860	Ny.Fm (Non PEB)	38	G1P0A0	1/2018 (40 minggu 1 h	1	0	28,84	100	60	**9.52**	0	bhayangkara
35	18125549	Ny. Sy (Non PEB)	31	G1P0A0	4/01/2018 (41 minggu	1	0	23,91	120	80	**3.73**	0	Fatimah
36	1884940	Ny. Ra (Non PEB)	26	G1P0A0	1/2018 (37 minggu 4 h	1	0	28,30	130	90	**11.9**	1	Fatimah
37	18125620	Ny. Sy (Non PEB)	33	G1P0A0	9/11/2017 (40 minggu	1	0	29,30	130	90	**8.79**	0	Fatimah
38	18165606	Ny. DD (Non PEB)	25	G1P0A0	/2018 (34 minggu 3 h	1	0	25,9	120	80	**19.3**	0	Fatimah
39	18125613	Ny. Nad (Non PEB)	28	G1P0A0	1/2018 (39 minggu 2 h	1	0	27,42	130	80	**9.34**	1	Fatimah
40	18125545	Ny. Nli (NON PEB)	19	G1P0A0	8/01/2018 (39 minggu	1	0	25,1	120	80	**8.03**	0	Fatimah
41	1882135	Ny. Nn (Non PEB)	21	G1P0A0	1/2018 (36 minggu 4h	1	0	29,43	130	90	**14.7**	0	Fatimah
42	82224	Ny. Nr (Non PEB)	21	G1P0A0	2/2018 (38 minggu 5h	1	0	26	130	80	**11.3**	0	khadijah
43	84777	Ny. Muay (Non PEB)	26	G1P0A0	40 minggu	1	0	25,10	120	80	**8.99**	0	khadijah
44	107308	Ny. RiAr (Non PEB)	33	G1P0A0	2/2018 (37 minggu 1 h	1	0	25,17	110	70	**9.42**	0	pertiwi
45	66802	Ny. F (Non PEB)	35	G1P0A0	2/2017 (39 minggu 3 h	1	0	29,64	130	70	**12.9**	0	pertiwi
46	107347	Ny. O (Non PEB)	13	G1P0A0	37 minggu	1	0	26,02	110	80	**14.1**	0	pertiwi
47	108321	Ny. S (Non PEB)	27	G1P0A0	2/2018 (39 minggu 2 h	1	0	26,66	110	80	**16.4**	0	pertiwi
48	107828	Ny. Md (Non PEB)	22	G1P0A0	2/2018 (39 minggu 3 h	1	0	24,56	110	70	**9.51**	0	pertiwi
49	108000	Ny. Rii (Non PEB)	21	G1P0A0	/2018 (40 minggu 6 ha	1	0	23,53	120	70	**18.7**	0	pertiwi
50	107305	Ny. S (Non PEB)	26	G1P0A0	4/12/2017 (40 minggu	1	0	30,5	130	80	**11.1**	0	pertiwi
51	107312	Ny. Hik (Non PEB)	34	G1P0A0	10/1/2018 (39 minggu	1	0	29,1	130	90	**7.28**	0	pertiwi
52	107305	Ny. Ri (Non PEB)	28	G1P0A0	0/01/2018 (39 minggu	1	0	30,44	130	80	**17.6**	0	pertiwi
53	309893	Ny. Jo (Non PEB)	18	G1P0A0	/2018 (40 minggu 2 h	1	0	25	120	70	**10.6**	0	bhayangkara
54	18125623	Ny. HeAr (Non PEB)	25	G1P0A0	8/02/2018 (39 minggu	1	0	25	120	80	**10.8**	0	Fatimah
55	134532	Ny. Nk (Non PEB)	30	G1P0A0	2/2018 (37 minggu 2h	1	0	27,6	120	80	**13.6**	0	bhayangkara
56	18124912	Ny. Ft (Non PEB)	24	G1P0A0	/2018 (39 minggu 5 ha	1	0	28,35	120	80	**16.5**	0	Fatimah
57	309293	Ny. DP (Non PEB)	22	G1P0A0	3/2018 (38 minggu 3 h	1	0	28	120	80	**16.4**	0	bhayangkara
58	82339	Ny. Nl (PEB)	36	G2P0A1	0/02/2018 (38 minggu	1	1	28,69	170	100	**11.5**	2	khadijah
59	18124862	Ny. Mt (PEB)	30	G2P1A0	05/02/2018 (38 minggu 1 hari)	1	1	24,03	180	110	**8.68**	2	Fatimah

60	18123482	Ny. IS (PEB)	34	G2P1A0	05/02/2018 (39minggu 5 hari)	1	1	26,29	160	100	**10.2**	2	Fatimah
61	18125540	Ny. Mr (PEB)	35	G2P1A0	8/1/2018 (39 minggu)	1	3	29,29	140	90	**14**	3	Fatimah
62	107682	Ny. Rah(PEB)	33	G2P1A0	2/2018 (38 minggu 2 h	1	1	30,11	180	120	**11.1**	2	pertiwi
63	18136680	Ny. An (PEB)	34	G2P1A0	2/2018 (38 minggu 2 h	1	2	31,25	160	110	**14.4**	2	Fatimah
64	300803	Ny. De (PEB)	29	G2P1A0	17/1/2018(40 minggu)	1	2	30,1	150	110	**14.6**	2	bhayangkara
65	497263	Ny. Nu (PEB)	31	G2P1A0	3/01/2018 (40 minggu	1	2	30,8	150	110	**17.9**	3	pertiwi
66	70078	Ny. Jn (PEB)	29	G2P1A0	37 minggu	1	1	26,10	160	100	**15.2**	2	pertiwi
67	23217	Ny. M (PEB)	27	G2P1A0	34 minggu	1	2	25,51	160	100	**9.82**	2	khadijah
68	84930	Ny. Hs (PEB)	30	G2P1A0	3/2018 (35 minggu 2 h	1	1	22,22	160	100	**11.1**	3	khadijah
69	85242	Ny. SP (Non PEB)	24	G2P1A0	12018 (38 minggu 2 ha	1	2	28,84	110	80	**7.92**	0	pertiwi
70	85325	Ny. DF (PEB)	29	G2P1A0	0/02/2018 (40 minggu	1	1	30	160	110	**9.37**	2	khadijah
71	188125538	Ny. DN (Non PEB)	18	G2P1A0	38 minggu	1	1	23,73	110	80	**12.5**	0	Fatimah
72	18124951	Ny. Ni (Non PEB)	20	G2P1A0	1/2018 (39 minggu 2 h	1	1	29,04	120	90	**14.9**	0	Fatimah
73	83816	Ny. Ris (Non PEB)	44	G2P1A0	1/2018 (37 minggu 3 h	1	2	30,04	120	80	**11.2**	0	khadijah
74	73588	Ny. Ang (Non PEB)	30	G2P1A0	2/01/2018 (40 minggu	1	1	28,01	120	80	**19.1**	0	khadijah
75	84697	Ny. FS (Non PEB)	32	G2P1A0	36 minggu	1	4	22,22	120	80	**11.2**	0	khadijah
76	104850	Ny. Nj (Non PEB)	23	G2P1A0	/2018 (39 minggu 3 ha	1	0	24,21	110	70	**6.83**	0	pertiwi
77	106724	Ny. Sj (Non PEB)	23	G2P1A0	2/2018 (38 minggu 5 h	1	2	25,80	110	60	**13.2**	0	pertiwi
78	60685	Ny. Mr (Non PEB)	36	G2P1A0	2/1/2018 (41 minggu)	1	3	31,2	130	80	**16.1**	1	pertiwi
79	107868	Ny. SN (Non PEB)	31	G2P1A0	2/12/2017 (40 minggu	1	2	30,8	120	80	**49.7**	1	pertiwi
80	308849	Ny. Pt (Non PEB)	32	G2P1A0	8/2/2018 (38 minggu)	1	2	27,5	100	70	**8.32**	0	bhayangkara
81	18124981	Ny. Rh (PEB)	36	G3P1A1	03/02/2018 (39 minggu)	1	2	24,8	150	110	**12.7**	2	Fatimah
82	859568	Ny. Fe (PEB)	39	G3P2A0	34 minggu	1	3	31,29	220	140	**10.1**	3	wahidin
83	89263	Ny. Mu (PEB)	37	G3P2A0	8/01/2018 (38 minggu	1	3	28,5	150	110	**7.16**	3	khadijah
84	18125598	Ny. AF (Non PEB)	26	G3P2A0	2/2018 (37 minggu 5 h	1	2	30,52	120	70	**13.4**	0	Fatimah
85	87474	Ny. N (Non PEB)	31	G3P2A0	/2018 (35 minggu 3 ha	1	3	28,35	130	80	**12.6**	1	khadijah
86	37429	Ny. S (PEB)	46	G4P2A1	3/2018 (39 minggu 2 h	1	2	25,39	160	110	**6.02**	2	khadijah
87	18125522	Ny. St (non PEB)	38	G4P3A0	1/2018 (39 minggu 4 h	1	2	27,77	110	80	**12.4**	0	Fatimah
88	858007	Ny. H (Non PEB)	42	G4P3A0	7/12/2017 (40 minggu	1	5	23,31	120	70	**4.34**	0	wahidin
89	96313	Ny. EL (PEB)	38	G5P2A2	2/2017 (41 minggu 1 h	1	2	33,33	160	100	**8.36**	3	pertiwi
90	18125655	Ny. Ra (Non PEB)	45	G6P5A0	1/2017 (39 minggu 3 h	1	3	31.25	130	90	**9.23**	0	Fatimah

Lampiran 9


STATUS PREEKLEMPSIA
Frequency
50
40
30
20
10
0
Non PEB
PEB
STATUS PREEKLEMPSIA


USIA
Frequency
8
6
4
2
0
13 15 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 42 44 45 46
USIA


KATEGORI USIA
Frequency
80
60
40
20
0
< 35 tahun
>= 35 tahun
KATEGORI USIA


PARITAS
Frequency
60
50
40
30
20
10
0
Primigravida
Multigravida
PARITAS


USIA KEHAMILAN
Frequency
40
30
20
10
0
34
35
36
37
38
39
40
41
USIA KEHAMILAN


KEHAMILAN
Frequency
100
80
60
40
20
0
Tunggal
KEHAMILAN


JARAK ANTAR KEHAMILAN
Frequency
60
50
40
30
20
10
0
.0
1.0
2.0
3.0
4.0
5.0
JARAK ANTAR KEHAMILAN


INDEKS MASSA TUBUH
Frequency
3
2
1
0
22.220
23.310
23.730
24.030
24.560
25.000
25.170
25.510
25.800
26.000
26.100
26.290
26.660
27.300
27.400
27.500
27.770
27.920
28.010
28.200
28.350
28.500
28.700
28.900
29.100
29.290
29.430
30.000
30.100
30.150
30.440
30.520
30.830
31.200
31.290
33.290
34.540
INDEKS MASSA TUBUH


TD SISTOLIK
Frequency
25
20
15
10
5
0
100
110
120
130
140
150
160
170
180
190
200
220
TD SISTOLIK


TD DIASTOLIK
Frequency
25
20
15
10
5
0
60
70
80
90
100
110
120
140
TD DIASTOLIK


NEFRINURIN
Frequency
2.0
1.5
1.0
0.5
0.0
3.73
4.98
6.82
7.28
7.92
8.32
8.79
9.23
9.42
9.51
10.13
10.35
10.76
10.93
11.14
11.32
12.39
12.47
12.70
12.98
13.20
13.56
14.42
14.71
16.03
16.44
17.57
18.68
19.76
45.57
NEFRINURIN


PROTEINURIA
Frequency
50
40
30
20
10
0
0
1
2
3
PROTEINURIA

Tests of Normality[c,d]

	STATUS PREEKLEMPSIA	Kolmogorov-Smirnov[a]		
		Statistic	df	Sig.
NEFRINURIN	Non PEB	.159	46	.005
	PEB	.204	44	.000
USIA	Non PEB	.104	46	.200*
	PEB	.157	44	.008
KATEGORI USIA	Non PEB	.501	46	.000
	PEB	.466	44	.000
PARITAS	Non PEB	.417	46	.000
	PEB	.397	44	.000
USIA KEHAMILAN	Non PEB	.257	46	.000
	PEB	.224	44	.000
JARAK ANTAR KEHAMILAN	Non PEB	.400	46	.000
	PEB	.370	44	.000
INDEKS MASSA TUBUH	Non PEB	.078	46	.200*
	PEB	.063	44	.200*
SISTOLIK	Non PEB	.214	46	.000
	PEB	.307	44	.000
DIASTOLIK	Non PEB	.297	46	.000
	PEB	.283	44	.000
PROTEINURIA	Non PEB	.526	46	.000
	PEB	.386	44	.000

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

c. KEHAMILAN is constant when STATUS PREEKLEMPSIA = Non PEB. It has been omitted.

d. KEHAMILAN is constant when STATUS PREEKLEMPSIA = PEB. It has been omitted.

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.782[a]	1	.377		
Continuity Correction[b]	.392	1	.531		
Likelihood Ratio	.784	1	.376		
Fisher's Exact Test				.444	.266
Linear-by-Linear Association	.773	1	.379		
N of Valid Cases	90				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 9.29.

b. Computed only for a 2x2 table

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.144[a]	1	.705		
Continuity Correction[b]	.026	1	.873		
Likelihood Ratio	.144	1	.705		
Fisher's Exact Test				.827	.436
Linear-by-Linear Association	.142	1	.706		
N of Valid Cases	90				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 16.13.

b. Computed only for a 2x2 table

Test Statistics[a]

	TD SISTOLIK	TD DIASTOLIK	NEFRINURIN	PROTEINURIA
Mann-Whitney U	.000	8.000	902.000	.000
Wilcoxon W	1081.000	1089.000	1983.000	1081.000
	-8.286	-8.303	-.888	-8.741
Asymp. Sig. (2-tailed)	.000	.000	.375	.000

a. Grouping Variable: STATUS PREEKLEMPSIA

Report

STATUS PREEKLEMPSIA		KATEGORI USIA	PARITAS	USIA KEHAMILAN	TD SISTOLIK	TD DIASTOLIK	NEFRINURIN	PROTEINURIA
Non PEB	Mean	1.17	1.35	38.52	120.22	78.48	12.1720	.11
		46	46	46	46	46	46	46
	Std. Deviation	.383	.482	1.487	8.816	7.592	6.86875	.315
PEB	Mean	1.25	1.39	38.34	163.86	107.27	13.1384	2.41

	44	44	44	44	44	44	44
Std. Deviation	.438	.493	1.642	14.819	8.453	6.61642	.497
Mean	1.21	1.37	38.43	141.56	92.56	12.6444	1.23
Total	90	90	90	90	90	90	90
Std. Deviation	.410	.485	1.558	25.035	16.528	6.72619	1.227

analisis berdasarkan faktor risiko terjadinya status preeklampsia, yakni berdasarkan usia dan paritas dengan menggunakan uji *Mann Whitney*

Report

NEFRINURIN

KATEGORI USIA	STATUS PREEKLEMPSIA	Mean	N	Std. Deviation
	Non PEB	12.6113	38	7.29731
< 35 tahun	PEB	13.7930	33	7.15966
	Total	13.1606	71	7.20643
	Non PEB	10.0850	8	3.97549
>= 35 tahun	PEB	11.1745	11	4.30705
	Total	10.7158	19	4.09361
	Non PEB	12.1720	46	6.86875
Total	PEB	13.1384	44	6.61642
	Total	12.6444	90	6.72619

Report

NEFRINURIN

RITAS	ATUS PREEKLEMPSIA	Mean	N	Std. Deviation
	Non PEB	11.2403	30	4.08978
Primigravida	PEB	14.2963	27	7.92283
	Total	12.6879	57	6.33841
	ı PEB	13.9188	16	10.20838
Multigravida	PEB	11.2994	17	3.12922
	Total	12.5694	33	7.45065
	ı PEB	12.1720	46	6.86875
Total	PEB	13.1384	44	6.61642
	Total	12.6444	90	6.72619

NON PEB

Test Statistics[a]

	NEFRINURIN
Mann-Whitney U	124.000
Wilcoxon W	160.000
	-.811
Asymp. Sig. (2-tailed)	.417
Exact Sig. [2*(1-tailed Sig.)]	.433[b]

a. Grouping Variable: KATEGORI USIA

b. Not corrected for ties.

Test Statistics[a]

	NEFRINURIN
Mann-Whitney U	211.000
Wilcoxon W	676.000
	-.669
Asymp. Sig. (2-tailed)	.504

a. Grouping Variable: PARITAS

PEB

Test Statistics[a]

	NEFRINURIN
Mann-Whitney U	135.000
Wilcoxon W	201.000
	-1.260
Asymp. Sig. (2-tailed)	.208
Exact Sig. [2*(1-tailed Sig.)]	.216[b]

a. Grouping Variable: KATEGORI USIA

b. Not corrected for ties.

Test Statistics[a]

	NEFRINURIN
Mann-Whitney U	175.500
Wilcoxon W	328.500
	-1.302
Asymp. Sig. (2-tailed)	.193

a. Grouping Variable: PARITAS

Kehamilan PEB

Statistics

		TD SISTOLIK	TD DIASTOLIK
N	Valid	44	44
	Missing	0	0
Mean		163.86	107.27
Median		160.00	110.00
Mode		160	110
Std. Deviation		14.819	8.453
Variance		219.609	71.459
Minimum		140	90
Maximum		220	140
Percentiles	10	150.00	100.00
	20	150.00	100.00
	25	160.00	100.00
	30	160.00	100.00
	40	160.00	110.00
	50	160.00	110.00
	60	160.00	110.00
	70	165.00	110.00
	75	170.00	110.00
	80	170.00	110.00
	90	185.00	115.00

Descriptives

			Statistic	Std. Error
TD SISTOLIK	Mean		163.86	2.234
	95% Confidence Interval for Mean	Lower Bound	159.36	
		Upper Bound	168.37	
	5% Trimmed Mean		162.42	
	Median		160.00	
	Variance		219.609	
	Std. Deviation		14.819	
	Minimum		140	
	Maximum		220	
	Range		80	
	Interquartile Range		10	
	Skewness		1.759	.357
	Kurtosis		4.232	.702
TD DIASTOLIK	Mean		107.27	1.274
	95% Confidence Interval for Mean	Lower Bound	104.70	
		Upper Bound	109.84	
	5% Trimmed Mean		106.97	
	Median		110.00	
	Variance		71.459	
	Std. Deviation		8.453	
	Minimum		90	
	Maximum		140	
	Range		50	
	Interquartile Range		10	
	Skewness		1.050	.357
	Kurtosis		4.343	.702

Statistics

		NEFRINURIN	PROTEINURIA
N	Valid	44	44
	Missing	0	0
Mean		13.1384	2.41
Median		11.9800	2.00
Mode		11.14	2
Std. Deviation		6.61642	.497
Variance		43.777	.247
Minimum		6.02	2
Maximum		45.57	3
Percentiles	10	7.2900	2.00
	20	9.3700	2.00
	25	9.5575	2.00
	30	10.1600	2.00
	40	10.9300	2.00
	50	11.9800	2.00
	60	12.7800	3.00
	70	13.7300	3.00
	75	14.5325	3.00
	80	15.1600	3.00
	90	19.1150	3.00

Descriptives

			Statistic	Std. Error
NEFRINURIN	Mean		13.1384	.99746
	95% Confidence Interval for Mean	Lower Bound	11.1268	
		Upper Bound	15.1500	
	5% Trimmed Mean		12.2486	
	Median		11.9800	
	Variance		43.777	
	Std. Deviation		6.61642	
	Minimum		6.02	
	Maximum		45.57	
	Range		39.55	
	Interquartile Range		4.98	
	Skewness		3.154	.357
	Kurtosis		13.423	.702
PROTEINURIA	Mean		2.41	.075
	95% Confidence Interval for Mean	Lower Bound	2.26	
		Upper Bound	2.56	
	5% Trimmed Mean		2.40	
	Median		2.00	
	Variance		.247	
	Std. Deviation		.497	
	Minimum		2	
	Maximum		3	
	Range		1	
	Interquartile Range		1	
	Skewness		.383	.357
	Kurtosis		-1.944	.702

Kehamilan normal

Statistics

		TD SISTOLIK	TD DIASTOLIK
N	Valid	46	46
	Missing	0	0
Mean		120.22	78.48
Median		120.00	80.00
Mode		120	80
Std. Deviation		8.816	7.592
Variance		77.729	57.633
Minimum		100	60
Maximum		130	90
Percentiles	10	110.00	70.00
	20	110.00	70.00
	25	110.00	70.00
	30	120.00	80.00
	40	120.00	80.00
	50	120.00	80.00
	60	120.00	80.00
	70	130.00	80.00
	75	130.00	80.00
	80	130.00	80.00
	90	130.00	90.00

Descriptives

			Statistic	Std. Error
TD SISTOLIK	Mean		120.22	1.300
	95% Confidence Interval for Mean	Lower Bound	117.60	
		Upper Bound	122.84	
	5% Trimmed Mean		120.72	
	Median		120.00	
	Variance		77.729	
	Std. Deviation		8.816	
	Minimum		100	
	Maximum		130	
	Range		30	
	Interquartile Range		20	
	Skewness		-.450	.350
	Kurtosis		-.687	.688
TD DIASTOLIK	Mean		78.48	1.119
	95% Confidence Interval for Mean	Lower Bound	76.22	
		Upper Bound	80.73	
	5% Trimmed Mean		78.79	
	Median		80.00	
	Variance		57.633	
	Std. Deviation		7.592	
	Minimum		60	
	Maximum		90	
	Range		30	
	Interquartile Range		10	
	Skewness		-.372	.350
	Kurtosis		.085	.688

Statistics

		NEFRINURIN	PROTEINURIA
N	Valid	46	46
	Missing	0	0
Mean		12.1720	.11
Median		11.1500	.00
Mode		3.73[a]	0
Std. Deviation		6.86875	.315
Variance		47.180	.099
Minimum		3.73	0
Maximum		49.66	1
Percentiles	10	6.2750	.00
	20	8.1460	.00
	25	8.8650	.00
	30	9.2410	.00
	40	10.0960	.00
	50	11.1500	.00
	60	12.4040	.00
	70	13.3320	.00
	75	14.2375	.00
	80	15.5860	.00
	90	17.9030	1.00

a. Multiple modes exist. The smallest value is shown

Descriptives

			Statistic	Std. Error
NEFRINURIN	Mean		12.1720	1.01274
	95% Confidence Interval for Mean	Lower Bound	10.1322	
		Upper Bound	14.2117	
	5% Trimmed Mean		11.4928	
	Median		11.1500	
	Variance		47.180	
	Std. Deviation		6.86875	
	Minimum		3.73	
	Maximum		49.66	
	Range		45.93	
	Interquartile Range		5.37	
	Skewness		3.687	.350
	Kurtosis		19.633	.688
PROTEINURIA	Mean		.11	.046
	95% Confidence Interval for Mean	Lower Bound	.02	
		Upper Bound	.20	
	5% Trimmed Mean		.07	
	Median		.00	
	Variance		.099	
	Std. Deviation		.315	
	Minimum		0	
	Maximum		1	
	Range		1	
	Interquartile Range		0	
	Skewness		2.600	.350
	Kurtosis		4.974	.688

uji hubungan antara proteinuria dan nefrinuria pada kelompok kehamilan normal dan preeklampsia berat dengan menggunakan uji spearman

Correlations

			NEFRINURIN	PROTEINURIA
Spearman's rho	NEFRINURIN	Correlation Coefficient	1.000	.114
		Sig. (2-tailed)	.	.462
		N	44	44
	PROTEINURIA	Correlation Coefficient	.114	1.000
		Sig. (2-tailed)	.462	.
		N	44	44